<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1348076</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1348076</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Natural products reverse cancer multidrug resistance</article-title>
<alt-title alt-title-type="left-running-head">Zou et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1348076">10.3389/fphar.2024.1348076</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zou</surname>
<given-names>Jia-Yu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Chen</surname>
<given-names>Qi-Lei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1904551/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Luo</surname>
<given-names>Xiao-Ci</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Damdinjav</surname>
<given-names>Davaadagva</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abdelmohsen</surname>
<given-names>Usama Ramadan</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/605663/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Hong-Yan</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Battulga</surname>
<given-names>Tungalag</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Hu-Biao</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/825977/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Yu-Qing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1381890/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Jian-Ye</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/534309/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target &#x26; Clinical Pharmacology</institution>, <institution>The NMPA and State Key Laboratory of Respiratory Disease</institution>, <institution>School of Pharmaceutical Sciences and the Fifth Affiliated Hospital</institution>, <institution>Guangzhou Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>School of Chinese Medicine</institution>, <institution>Hong Kong Baptist University</institution>, <addr-line>Kowloon</addr-line>, <country>Hong Kong SAR, China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>School of Pharmacy</institution>, <institution>Mongolian National University of Medical Sciences</institution>, <addr-line>Ulaanbaatar</addr-line>, <country>Mongolia</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Deraya Center for Scientific Research</institution>, <institution>Deraya University</institution>, <addr-line>New Minia</addr-line>, <country>Egypt</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Pharmacognosy</institution>, <institution>Faculty of Pharmacy</institution>, <institution>Minia University</institution>, <addr-line>Minia</addr-line>, <country>Egypt</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Ministry of Education Engineering Research Center of Tibetan Medicine Detection Technology</institution>, <institution>Xizang Minzu University</institution>, <addr-line>Xianyang</addr-line>, <country>China</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>The Affiliated TCM Hospital</institution>, <institution>Guangzhou Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff8">
<sup>8</sup>
<institution>The Affiliated Qingyuan Hospital</institution>, <institution>Guangzhou Medical University</institution>, <addr-line>Qingyuan</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1387948/overview">Yan Zhang</ext-link>, Shenyang Pharmaceutical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/450113/overview">Radhika Amaradhi</ext-link>, University of Texas at San Antonio, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/845344/overview">Berna Dogan</ext-link>, Istanbul Technical University, T&#xfc;rkiye</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2616088/overview">Andleeb Sardar</ext-link>, Government College University, Pakistan</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Davaadagva Damdinjav, <email>dagvaa1972@yahoo.com</email>; Hu-Biao Chen, <email>hbchen@hkbu.edu.hk</email>; Yu-Qing Wang, <email>wangyuq@gzhmu.edu.cn</email>; Jian-Ye Zhang, <email>jianyez@163.com</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1348076</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>12</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>02</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Zou, Chen, Luo, Damdinjav, Abdelmohsen, Li, Battulga, Chen, Wang and Zhang.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Zou, Chen, Luo, Damdinjav, Abdelmohsen, Li, Battulga, Chen, Wang and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Cancer stands as a prominent global cause of death. One of the key reasons why clinical tumor chemotherapy fails is multidrug resistance (MDR). In recent decades, accumulated studies have shown how Natural Product-Derived Compounds can reverse tumor MDR. Discovering novel potential modulators to reduce tumor MDR by Natural Product-Derived Compounds has become a popular research area across the globe. Numerous studies mainly focus on natural products including flavonoids, alkaloids, terpenoids, polyphenols and coumarins for their MDR modulatory activity. Natural products reverse MDR by regulating signaling pathways or the relevant expressed protein or gene. Here we perform a deep review of the previous achievements, recent advances in the development of natural products as a treatment for MDR. This review aims to provide some insights for the study of multidrug resistance of natural products.</p>
</abstract>
<kwd-group>
<kwd>mechanism</kwd>
<kwd>natural product-derived compounds</kwd>
<kwd>cancer</kwd>
<kwd>multidrug resistance</kwd>
<kwd>MDR</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pharmacology of Anti-Cancer Drugs</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>According to the World Health Organization (WHO) and International Agency for Cancer Research, there were approximately 19.3 million new cases of cancer in the past (<xref ref-type="bibr" rid="B137">Rudnicka et al., 2020</xref>), along with around 10 million cancer-related deaths (<xref ref-type="bibr" rid="B150">Sung et al., 2021</xref>). Cancer was one of the leading causes of mortality worldwide, and there were likely 28.4 million new cases by the year 2040 (<xref ref-type="bibr" rid="B143">Siegel et al., 2023</xref>). Chemotherapy could be confidently recommended for first-line treatment. MDR was a phenomenon in which cancer cells acquired cross-resistance to structurally and functionally related different types of anticancer drugs. However, the emergence of drug resistance made chemotherapy much less effective (<xref ref-type="bibr" rid="B111">Lu et al., 2022</xref>). Scientists have shown an interest in natural products (<xref ref-type="bibr" rid="B188">Zhang et al., 2020</xref>) because of their superiority in terms of rich resources, lack of negative side effects, and variety of components. Various biological actions are demonstrated by natural compounds, such as anti-tumor (<xref ref-type="bibr" rid="B115">Mans et al., 2000</xref>), anti-microbial (<xref ref-type="bibr" rid="B17">Chakrawarti et al., 2016</xref>; <xref ref-type="bibr" rid="B116">Martinelli et al., 2021</xref>; <xref ref-type="bibr" rid="B126">Papadochristopoulos et al., 2021</xref>), antioxidant (<xref ref-type="bibr" rid="B8">Arulselvan et al., 2016</xref>; <xref ref-type="bibr" rid="B64">Huang et al., 2017</xref>), anti-inflammatory (<xref ref-type="bibr" rid="B8">Arulselvan et al., 2016</xref>; <xref ref-type="bibr" rid="B64">Huang et al., 2017</xref>), anti-diabetic (<xref ref-type="bibr" rid="B27">Chen W. et al., 2019</xref>; <xref ref-type="bibr" rid="B113">Luo et al., 2019</xref>), anti-hypertensive (<xref ref-type="bibr" rid="B45">Fang et al., 2021</xref>; <xref ref-type="bibr" rid="B57">Gupta et al., 2022</xref>), anti-atherogenic (<xref ref-type="bibr" rid="B128">Penson and Banach, 2021</xref>), gastro-protective (<xref ref-type="bibr" rid="B151">Tamaddonfard et al., 2019</xref>), anti-platelets (<xref ref-type="bibr" rid="B72">Iqbal et al., 2022</xref>), anti-thrombotic (<xref ref-type="bibr" rid="B35">Csik&#xf3;s et al., 2021</xref>; <xref ref-type="bibr" rid="B75">Junren et al., 2021</xref>; <xref ref-type="bibr" rid="B181">Yen et al., 2022</xref>) vital effects on reversing MDR (<xref ref-type="bibr" rid="B56">Guo et al., 2017</xref>; <xref ref-type="bibr" rid="B162">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="B194">Zhao et al., 2020</xref>).</p>
<p>The application of natural products in MDR has received much attention recently. This review examines the scientific advances on using natural products to treat tumors with MDR. We discuss the mechanisms of action of various kinds of natural products, including as flavonoids (<xref ref-type="bibr" rid="B160">Vissenaekens et al., 2022</xref>), alkaloids (<xref ref-type="bibr" rid="B100">Liu C. et al., 2019</xref>), terpenoids (<xref ref-type="bibr" rid="B83">Kuang et al., 2021</xref>), polyphenols (<xref ref-type="bibr" rid="B112">Luca et al., 2020</xref>), and coumarins (<xref ref-type="bibr" rid="B173">Xiaokaiti and Li, 2020</xref>; <xref ref-type="bibr" rid="B52">Giovannuzzi et al., 2022</xref>).</p>
</sec>
<sec id="s2">
<title>2 The mechanism of MDR</title>
<p>MDR refers to a cancer cell&#x2019;s sensitivity to various anti-cancer medication therapies (<xref ref-type="bibr" rid="B9">Assaraf et al., 2019</xref>). Nevertheless, setting out the factors related to MDR could benefit the administration of antitumor drugs and curation (<xref ref-type="bibr" rid="B111">Lu et al., 2022</xref>). This paper describes the mechanisms of MDR, such as increasing drug efflux, altering drug targets, increasing DNA damage repair, MDR-related factors or signaling pathways, non-coding RNA (ncRNA)-mediated multidrug resistance, and autophagy and tumor microenvironment effects.</p>
<sec id="s2-1">
<title>2.1 Increasing of drug efflux</title>
<p>Cancer cells exhibiting MDR typically increase the efflux of drug molecules, which reduces the chemosensitivity to anticancer medicines (<xref ref-type="bibr" rid="B119">Mohammad et al., 2018</xref>; <xref ref-type="bibr" rid="B2">Abdelfatah et al., 2021</xref>). Some genes associated with multidrug resistance in cancer are very unstable. For example, the CDK6 and CDK6-PI3K axes act synergistically in regulating ABCB1/P-gp-mediated expression of MDR (<xref ref-type="bibr" rid="B187">Zhang L. et al., 2022</xref>). It has been noted that long-term use of chemotherapy medicines increases the expression of the ABC transporter, thereby raising the risk of MDR. The ABC transporter by ATP hydrolysis move substrates outward against a concentration gradient (<xref ref-type="bibr" rid="B73">Jacobo-Albavera et al., 2021</xref>). For this reason, ATP-binding cassette sub-family B member 1, also known as P-glycoprotein (ABCB1/P-gp), ATP-binding cassette sub-family C member 1/Multidrug resistance-associated proteins (ABCC1/MRPs), and ATP-binding cassette sub-family G member 2/Breast cancer resistance protein (ABCG2/BCRP) are the most important drug transporters.</p>
<p>P-gp is present in both healthy and malignant cells (<xref ref-type="bibr" rid="B142">Sarkadi et al., 2006</xref>). The transmembrane structural domain and the nucleotide-binding domain are the two primary structural domains that make up the P-gp transporter. The ABC protein&#x2019;s structure may change upon binding to ATP, leading to concurrent change in the substrate binding site, which causes the substrate drug to be expelled from the cell. Different chemotherapeutic medicines bind to P-gp, which modifies the structure of P-gp and releases the drug into the extracellular space as ATP is digested (<xref ref-type="bibr" rid="B9">Assaraf et al., 2019</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Mechanisms involved in cancer drug resistance.</p>
</caption>
<graphic xlink:href="fphar-15-1348076-g001.tif"/>
</fig>
<p>In various cancer types, such as lung, breast and prostate cancer, the expression of MRPs and BCRPs leads to resistance drugs (<xref ref-type="bibr" rid="B6">Ambudkar et al., 2003</xref>; <xref ref-type="bibr" rid="B53">Goel and Aggarwal, 2010</xref>). MRPs have the same structure and function as P-gp, but MRPs only transport medicines that have undergone glutathione (GSH) modification, and they have an impact on when pharmaceuticals are metabolically activated (<xref ref-type="bibr" rid="B101">Liu, 2009</xref>). Drugs are effluxed after MRPs create a complex with glutathione, glucuronate, or sulfate. Etoposide, doxorubicin (Dox), vincristine (VCR), and epirubicin (EPI) are among the drugs that are susceptible to MRPs (<xref ref-type="bibr" rid="B101">Liu, 2009</xref>). BCRP structure is homodimeric formed two-half transporters joined by a disulfide bond (<xref ref-type="fig" rid="F1">Figure 1</xref>). Such drugs as mitoxantrone, topotecan, Dox, irinotecan, EPI, and flavopiridol are sensitive to BCRP (<xref ref-type="bibr" rid="B6">Ambudkar et al., 2003</xref>; <xref ref-type="bibr" rid="B133">Robey et al., 2007</xref>).</p>
</sec>
<sec id="s2-2">
<title>2.2 Altering the drug targets</title>
<p>Creizotinib resistance in lung adenocarcinoma, caused by an acquired mutation in the glycine-to-arginine substitution at codon 2032 in the structural domain of reactive oxygen species (ROS) proto-oncogene 1 (ROS1) kinase (<xref ref-type="bibr" rid="B11">Awad et al., 2013</xref>). Similarly, secondary EGFR mutations in the outer structural domain S492R lead to cetuximab resistance by preventing EGFR antibodies from binding to their target sites in colon cancer (<xref ref-type="bibr" rid="B120">Montagut et al., 2012</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
</sec>
<sec id="s2-3">
<title>2.3 Increase in DNA damage repair</title>
<p>A major cause of tumor progression, is persistent genetic mutations have been occurring in the genome of cancer cells. The DNA damage response (DDR) is essential to protect cells from the large amount of oxidative damage to which they are periodically subjected by cellular damage (<xref ref-type="bibr" rid="B55">Groelly et al., 2023</xref>). DDR and cell cycle checkpoints are interlock signaling networks that can impede the cell cycle and transmission of genetic information to daughter cells to ensure genomic integrity (<xref ref-type="bibr" rid="B114">Maleki Dana et al., 2022</xref>). Cell cycle checkpoints enable the orderly progression of cell cycle events and avoid the development of genomic instability-related diseases such as cancer.</p>
<p>The G1 checkpoint is dysregulated in the majority of cancer cells, making them reliant on the S and G2 checkpoints, specifically ATR-CHK1. Cancer enhance their DNA repair system and promote survival by activating the ATR-CHK1 pathway. Chemotherapeutic drugs that target replicating DNA cells activate the ATR-CHK1 pathway (<xref ref-type="bibr" rid="B36">da Costa et al., 2023</xref>). Additionally, inhibitors of ATR-CHK1 have been reported to decrease the levels of P-gp (<xref ref-type="bibr" rid="B3">Ahmed et al., 2022</xref>).</p>
<p>Natural products, including curcumin, mangostin, resveratrol, and carnosine, block the G1-S phase but not affect the cell division cycle of proliferating healthy cells. Studies have shown that resveratrol, mangostin, and carnosine are agonists of ATR-CHK1, and kaempferol, curcumin, raffinose, and caffeine are inhibitors of ATR-CHK1, and these phytochemicals may help overcome tumor resistance (<xref ref-type="bibr" rid="B3">Ahmed et al., 2022</xref>). PU-1 is a sesquiterpenoid derived from Asteraceae that inhibits the growth of drug-resistant tumor cells through DNA damage, G2/M cell cycle blockade and apoptosis (<xref ref-type="bibr" rid="B59">Hegazy et al., 2021</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
</sec>
<sec id="s2-4">
<title>2.4 MDR-related factors or signaling pathways</title>
<p>Some transcription factors aid in the growth and resistance to chemotherapy of drug-resistant cancer cells. The transcription factor Nrf2 aids to the resistance to chemotherapy and to proliferation of cancer cells by control the expression of cytoprotective and antioxidant enzymes (<xref ref-type="bibr" rid="B51">Ghareghomi et al., 2022</xref>; <xref ref-type="bibr" rid="B125">Panieri et al., 2022</xref>). Another important Five transcription factors that make up NF-&#x3ba;B can attach to responsive gene promoter regions and control biological activities such DNA transcription, cytokine generation, and cell survival. Apoptosis suppression, tumor cell proliferation, and treatment resistance are all caused by activated NF-&#x3ba;B. Numerous cancer forms exhibit abnormal factor regulation, which is exacerbated by the presence of the majority of anticancer medications in the cancer cells (<xref ref-type="bibr" rid="B161">Vlahopoulos, 2017</xref>; <xref ref-type="bibr" rid="B171">Xia et al., 2018</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
</sec>
<sec id="s2-5">
<title>2.5 Non-coding RNA (ncRNA)-mediated multidrug resistance</title>
<p>Almost all cell processes, including transcription, proliferation, apoptosis, and differentiation, have been shown to be significantly regulated by non-coding RNAs (ncRNAs), particularly microRNA (<xref ref-type="bibr" rid="B199">Zou et al., 2017</xref>; <xref ref-type="bibr" rid="B178">Yang et al., 2021</xref>), long non-coding RNA (lncRNA) (<xref ref-type="bibr" rid="B144">Singh et al., 2022</xref>), and circular RNA. They also play a significant role in the regulation of cancer drug resistance (<xref ref-type="bibr" rid="B87">Leng et al., 2022</xref>). The expression of specific target genes, including Bcl-2, MDR1/ABCB1, and MRP1/ABCC1, which regulate apoptosis, autophagy, drug efflux, epithelial to mesenchymal transition (EMT), and cancer stem cells (CSCs), leads to the development of MDR. The interaction of ncRNAs with DNA, RNA, and proteins is the foundation for all of these mechanisms (<xref ref-type="bibr" rid="B196">Zhou et al., 2022a</xref>; <xref ref-type="bibr" rid="B89">Li et al., 2022</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
</sec>
<sec id="s2-6">
<title>2.6 Autophagy and tumor microenvironment effects</title>
<sec id="s2-6-1">
<title>2.6.1 Autophagy</title>
<p>Autophagy breaks down damaged organelles and stops cells from accumulating too many anticancer drugs, which encourages the growth of multidrug resistance in cancer cells (<xref ref-type="bibr" rid="B20">Chang and Zou, 2020</xref>). However, autophagy in the cellular surroundings can also eliminate MDR tumor cells, thereby enhancing the efficacy of chemotherapy. This process is regulated by various autophagy-related pathways and components, including ATG16L1, ATG5, the PI3K/AKT/mTOR pathway, AMP-activated protein kinase (AMPK), the miR199a-5p/p62 axis, p53, TFEB, and NSAIDs (<xref ref-type="bibr" rid="B37">Debnath et al., 2023</xref>). The activation of autophagy facilitates the removal of drug-resistant tumor cells, thus improving the overall response to chemotherapy (<xref ref-type="bibr" rid="B94">Li et al., 2017</xref>; <xref ref-type="bibr" rid="B130">Rakesh et al., 2022</xref>; <xref ref-type="bibr" rid="B174">Xing et al., 2022</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
</sec>
<sec id="s2-6-2">
<title>2.6.2 Tumor microenvironment (TME)</title>
<p>Low extracellular pH, increased ROS concentrations, hypoxia, and the overexpression of certain proteases and factors are TME characteristics (<xref ref-type="bibr" rid="B13">Barkley et al., 2022</xref>). TME has its own blood supply, lymphatic and neurological systems, stroma, immune cells, and Extracellular Matrix (ECM) for each person with a specific tumor (<xref ref-type="bibr" rid="B156">Tiwari et al., 2022</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<p>Under hypoxic conditions, TME demonstrates chemoresistance and reduces drug-induced cytotoxicity, which encourages cancer growth and spread. For optimum activity, several anticancer medications like Cisplatin (DDP), etoposide, and gemcitabine require oxygen (<xref ref-type="bibr" rid="B190">Zhang W. et al., 2022</xref>). A key factor in hypoxia-induced chemoresistance is the HIF protein. Under hypoxic conditions, Hif-1&#x3b1; encodes P-gp and increases the expression of MRP1, BCRP, and LRP. Additionally, Hif-1&#x3b1; supports DNA repair processes and inhibits the effects of chemotherapeutic drugs (<xref ref-type="bibr" rid="B42">Emran et al., 2022</xref>).</p>
<p>Another important component of MDR is the control of pH. According to research, MCF-7 cells are more resistant to the effects of chemotherapeutic medicines when the extracellular pH is lower (<xref ref-type="bibr" rid="B154">Tavares-Valente et al., 2013</xref>). The ATP-rich tumor microenvironment is associated with cancer drug resistance, and cancer cells are able to take up extracellular ATP (eATP) through macrocytosis to increase intracellular ATP (iATP) levels and enhance drug resistance. Elevated iATP upregulated ABC transporter efflux activity in A549 and SK-Hep-1 cells, as well as PDGFR&#x3b1; and protein phosphorylation in the PDGFR-mediated Akt-mTOR and Raf-MEK signaling pathways in A549 cells (<xref ref-type="bibr" rid="B165">Wang et al., 2017</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s3">
<title>3 Natural product&#x2014;derived compounds overcome cancer drug resistance mechanisms</title>
<p>Based on various studies, natural compounds do work as multifunctional agents that can control the main causes of MDR. Below, we outline how certain natural compounds, such as flavonoids, alkaloids, terpenoids, polyphenols, and coumarins, can contribute to reducing MDR.</p>
<sec id="s3-1">
<title>3.1 Flavonoids</title>
<p>In many different sections of plants, the most prevalent and significant secondary metabolites are flavonoids. Flavonoids, iso-flavonoids, and neo-flavonoids are the three types of flavonoids that can be distinguished by the presence of 2-phenylchromone ketone (<xref ref-type="bibr" rid="B41">Eichhorn and Efferth, 2012</xref>). These natural metabolites are frequently employed in clinical settings due to their anti-mutagenic, anti-oxidative, anti-inflammatory, and anti-carcinogenic effects as well as their ability to control important cellular enzymes (<xref ref-type="bibr" rid="B84">Kumar and Jaitak, 2019</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>; <xref ref-type="table" rid="T1">Table 1</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Chemical structures of Flavonoids having MDR modulatory activity.</p>
</caption>
<graphic xlink:href="fphar-15-1348076-g002.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The Effect of Natural Product-Derived Compounds on Cancer cells&#x2019; MDR.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left"/>
<th align="left">Compunds</th>
<th align="left">Cells</th>
<th align="left">Drug-resistant</th>
<th align="left">Mechanism</th>
<th align="left">ReF</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="40" align="left">Flavonoids</td>
<td rowspan="4" align="left">Dihydromyricetin</td>
<td align="left">HCT116</td>
<td align="left">OXA</td>
<td align="left">Inhibiting MRP2 expression and promoter</td>
<td align="left">
<xref ref-type="bibr" rid="B167">Wang et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">HCT8</td>
<td align="left">VCR</td>
<td align="left">Inhibiting MRP2 expression and promoter</td>
<td align="left">
<xref ref-type="bibr" rid="B167">Wang et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">SGC7901</td>
<td align="left">5-FU</td>
<td align="left">Regulation expression of MDR1 mRNA and protein</td>
<td align="left">
<xref ref-type="bibr" rid="B167">Wang et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">OvCa</td>
<td align="left">PTX; Dox</td>
<td align="left">Activation of p53</td>
<td align="left">
<xref ref-type="bibr" rid="B176">Xu et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Apigenin</td>
<td align="left">Human CD44<sup>&#x2b;</sup> prostate CSCs</td>
<td align="left">DDP</td>
<td align="left">Downregulation of anti-apoptotic Bcl-2, sharping and surviving; upregulation of pro-apoptotic caspase-8, Apaf-1 and p53 mRNA</td>
<td align="left">(<xref ref-type="bibr" rid="B43">Erdogan et al., 2016</xref>; <xref ref-type="bibr" rid="B44">Erdogan et al., 2017</xref>)</td>
</tr>
<tr>
<td align="left">A549; H1299</td>
<td align="left">OXA/BLM</td>
<td align="left">Elevate p53 and upregulate certain pro-apoptotic proteins</td>
<td align="left">
<xref ref-type="bibr" rid="B24">Chen et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">Acacetin</td>
<td align="left">A549; H1299</td>
<td align="left">OXA/BLM</td>
<td align="left">Inhibiting of BCRP</td>
<td align="left">(<xref ref-type="bibr" rid="B129">Punia et al., 2017</xref>; <xref ref-type="bibr" rid="B145">Singh et al., 2020</xref>)</td>
</tr>
<tr>
<td rowspan="8" align="left">Baicalein</td>
<td align="left">MDCKII</td>
<td align="left">silymarin</td>
<td align="left">Reverse P-gp</td>
<td align="left">(<xref ref-type="bibr" rid="B47">Ferreira et al., 2018a</xref>; <xref ref-type="bibr" rid="B48">Ferreira et al., 2018b</xref>)</td>
</tr>
<tr>
<td align="left">BEL7402</td>
<td align="left">Dox</td>
<td align="left">Decreases P-gp and anti-apoptotic Bcl-xl expression</td>
<td align="left">
<xref ref-type="bibr" rid="B90">Li et al. (2018b)</xref>
</td>
</tr>
<tr>
<td align="left">Thyroid carcinoma 8505c</td>
<td align="left">TXT/PTX</td>
<td align="left">Inhibiting of P-gp</td>
<td align="left">(<xref ref-type="bibr" rid="B118">Meng et al., 2016</xref>; <xref ref-type="bibr" rid="B127">Park et al., 2018</xref>)</td>
</tr>
<tr>
<td align="left">MCF-7</td>
<td align="left">PTX</td>
<td align="left">Inhibiting of P-gp</td>
<td align="left">(<xref ref-type="bibr" rid="B118">Meng et al., 2016</xref>; <xref ref-type="bibr" rid="B127">Park et al., 2018</xref>)</td>
</tr>
<tr>
<td align="left">Gastric AGS</td>
<td align="left">5-FU</td>
<td align="left">Inhibiting HIF-1&#x3b1; expression and Akt phosphorylation</td>
<td align="left">
<xref ref-type="bibr" rid="B22">Chen et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">DDP</td>
<td align="left">Inhibiting of PI3K/Akt/NF-&#x3ba;B signaling pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B183">Yu et al. (2017b)</xref>
</td>
</tr>
<tr>
<td align="left">PC3</td>
<td align="left">TRvAIL</td>
<td align="left">Induces ROS production and impact TME</td>
<td align="left">
<xref ref-type="bibr" rid="B180">Ye et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">breast cancer</td>
<td align="left">TAM</td>
<td align="left">Inhibiting HIF-1&#x3b1;-targeted glycolytic genes</td>
<td align="left">
<xref ref-type="bibr" rid="B29">Chen et al. (2021b)</xref>
</td>
</tr>
<tr>
<td rowspan="5" align="left">Wogonin</td>
<td align="left">K562</td>
<td align="left">A02/Dox</td>
<td align="left">Inhibiting functional activity and expression of P-gp at both protein and mRNA levels</td>
<td align="left">
<xref ref-type="bibr" rid="B175">Xu et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">HCT116/</td>
<td align="left">DDP</td>
<td align="left">Inhibiting PI3K/Akt signaling pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B58">He et al. (2013)</xref>
</td>
</tr>
<tr>
<td align="left">Human breast cancer</td>
<td align="left">sorafenib/Dox</td>
<td align="left">Downregulation IGF-1R/AKT signaling pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B134">Rong et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">TRAIL</td>
<td align="left">Induces ROS accumulation</td>
<td align="left">
<xref ref-type="bibr" rid="B179">Yang et al. (2013)</xref>
</td>
</tr>
<tr>
<td align="left">HNC</td>
<td align="left">DDP</td>
<td align="left">Inhibited Nrf2 and glutathione S-transferase P</td>
<td align="left">
<xref ref-type="bibr" rid="B180">Ye et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="left">Kaempferol</td>
<td align="left">OVCAR-3</td>
<td align="left">DDP</td>
<td align="left">Inhibits the mRNA levels of MRPs and cMyc</td>
<td align="left">
<xref ref-type="bibr" rid="B7">Amjad et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">HCT8-R</td>
<td align="left">5-FU</td>
<td align="left">Promotes the expression of miR-326, inhibit the process of glycolysis</td>
<td align="left">
<xref ref-type="bibr" rid="B169">Wu et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">CML</td>
<td align="left">TRAIL</td>
<td align="left">Enhance pro-apoptotic effects of anti-TRAIL antibody</td>
<td align="left">
<xref ref-type="bibr" rid="B141">Saraei et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">LS174-R</td>
<td align="left">5-FU</td>
<td align="left">Inhibiting reactive ROS; Modulated the expression of JAK/STAT3, MAPK, PI3K/AKT and NF-&#x3ba;B</td>
<td align="left">
<xref ref-type="bibr" rid="B132">Riahi-Chebbi et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="left">Quercetin</td>
<td align="left">BEL</td>
<td align="left">5-FU</td>
<td align="left">Inhibits the functions and downregulates the expressions of P-gp, MRPs</td>
<td align="left">
<xref ref-type="bibr" rid="B30">Chen et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">Breast CSCs</td>
<td align="left">Dox; PTX; VCR</td>
<td align="left">Downregulates P-gp expression</td>
<td align="left">
<xref ref-type="bibr" rid="B91">Li et al. (2018c)</xref>
</td>
</tr>
<tr>
<td align="left">MCF-7; 4T1; HCT116</td>
<td align="left">DDP; etoposide</td>
<td align="left">Regulates HIF-1&#x3b1;</td>
<td align="left">
<xref ref-type="bibr" rid="B81">Kim et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="left">Osteosarcoma 143B</td>
<td align="left">DDP</td>
<td align="left">Regulation miR-217-KRAS axis</td>
<td align="left">
<xref ref-type="bibr" rid="B191">Zhang et al. (2015b)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Galangin</td>
<td align="left">A2780/CP70; OVCAR-3</td>
<td align="left">DDP</td>
<td align="left">Increased the p53-dependent intrinsic and extrinsic apoptotic pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B65">Huang et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">DDP</td>
<td align="left">Inactivating p-STAT3/p65 and Bcl-2 pathways</td>
<td align="left">
<xref ref-type="bibr" rid="B184">Yu et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">Puerarin</td>
<td align="left">K562</td>
<td align="left">Dox</td>
<td align="left">Inhibited phosphorylation of Akt and JNK; Inhibition of NF-&#x3ba;B pathway; Downregulating MDR1</td>
<td align="left">
<xref ref-type="bibr" rid="B104">Liu et al. (2021b)</xref>
</td>
</tr>
<tr>
<td align="left">Genistein</td>
<td align="left">A549</td>
<td align="left">radiotherapy</td>
<td align="left">Downregulates the level of methylation in the Keap1 promoter region; Induces ROS production and impact TME</td>
<td align="left">(<xref ref-type="bibr" rid="B34">Cort et al., 2016</xref>; <xref ref-type="bibr" rid="B106">Liu et al., 2016</xref>)</td>
</tr>
<tr>
<td align="left">7,3&#x2032;,4&#x2032;-trihydroxyisoflavone</td>
<td align="left">HeLa</td>
<td align="left">EPI</td>
<td align="left">Down-regulating ABC transporters P-gp, MRPs</td>
<td align="left">
<xref ref-type="bibr" rid="B66">Hummelova et al. (2015)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="left">Luteolin</td>
<td align="left">KKU-100</td>
<td align="left">DDP</td>
<td align="left">Inhibiting of Nrf2</td>
<td align="left">
<xref ref-type="bibr" rid="B180">Ye et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">HCT116-OX; SW620-OX</td>
<td align="left">OXA</td>
<td align="left">Inhibiting of Nrf2</td>
<td align="left">
<xref ref-type="bibr" rid="B180">Ye et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Dox; BLM</td>
<td align="left">Inhibiting of Nrf2</td>
<td align="left">
<xref ref-type="bibr" rid="B180">Ye et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">MDA-MB 231</td>
<td align="left">Dox</td>
<td align="left">Inhibiting of Nrf2</td>
<td align="left">
<xref ref-type="bibr" rid="B180">Ye et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Chrysin</td>
<td align="left">MDA-MB-231</td>
<td align="left">mitoxantrone</td>
<td align="left">Inhibiting of P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B4">Ahmed-Belkacem et al. (2005)</xref>
</td>
</tr>
<tr>
<td align="left">MCF-7</td>
<td align="left">nitrofurantoin</td>
<td align="left">Regulate BCRP; Stimulating ATPase</td>
<td align="left">
<xref ref-type="bibr" rid="B4">Ahmed-Belkacem et al. (2005)</xref>
</td>
</tr>
<tr>
<td align="left">Ac15 (Az8)2</td>
<td align="left">S1M180</td>
<td align="left">topotecan</td>
<td align="left">Inhibiting BCRP-ATPase activity and drug efflux</td>
<td align="left">
<xref ref-type="bibr" rid="B32">Chong et al. (2022)</xref>
</td>
</tr>
<tr>
<td rowspan="13" align="left">Alkaloids</td>
<td align="left">Mono- and di-carbamate</td>
<td align="left">Human colon adenocarcinoma</td>
<td align="left">Dox</td>
<td align="left">Inhibition P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B140">Sancha et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="left">securinine</td>
<td align="left">HepG2</td>
<td align="left">Dox</td>
<td align="left">Inhibition P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B61">Hou et al. (2023)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">Tetrandrine</td>
<td align="left">Osteosarcoma</td>
<td align="left">Dox</td>
<td align="left">Changing the expression of MDR1 gene</td>
<td align="left">
<xref ref-type="bibr" rid="B197">Zhou et al. (2022b)</xref>
</td>
</tr>
<tr>
<td align="left">Hep-2</td>
<td align="left">VCR</td>
<td align="left">Inhibit MDR1</td>
<td align="left">
<xref ref-type="bibr" rid="B93">Li et al. (2020a)</xref>
</td>
</tr>
<tr>
<td align="left">YES-2</td>
<td align="left">DDP</td>
<td align="left">Inhibiting MRPs expression</td>
<td align="left">
<xref ref-type="bibr" rid="B162">Wang et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">Fangchinoline</td>
<td align="left">Caco-2; CEM/DOX5000</td>
<td align="left">Dox</td>
<td align="left">Inhibition P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Chan et al. (2021)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Oxymatrine</td>
<td align="left">CRC</td>
<td align="left">5-FU</td>
<td align="left">Induction of apoptosis; Suppressed expression of MRP1; Inactivated NF-&#x3ba;B signalling by decreasing phosphorylated p65</td>
<td align="left">
<xref ref-type="bibr" rid="B25">Chen et al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="left">CRC</td>
<td align="left">OXA</td>
<td align="left">Inhibiting of the NF-&#x3ba;B/PI3K/AKT/mTOR signal pathways</td>
<td align="left">
<xref ref-type="bibr" rid="B25">Chen et al. (2021a)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Matrine</td>
<td align="left">HT-29</td>
<td align="left">OXA</td>
<td align="left">Suppressed the expression of LRP and P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B95">Li et al. (2020b)</xref>
</td>
</tr>
<tr>
<td align="left">K562</td>
<td align="left">Dox</td>
<td align="left">Promoting autophagy; Arresting the cell cycle</td>
<td align="left">
<xref ref-type="bibr" rid="B95">Li et al. (2020b)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Rutaecarpine</td>
<td align="left">MCF-7</td>
<td align="left">Dox</td>
<td align="left">Inhibiting the expression of P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B198">Zou et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">PTX</td>
<td align="left">Inhibiting the expression of P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B198">Zou et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Voacamine</td>
<td align="left">U-2 OS-DX</td>
<td align="left">Dox</td>
<td align="left">Interfered with the P-gp-mediated drugs export acting</td>
<td align="left">
<xref ref-type="bibr" rid="B33">Condello et al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="12" align="left">Polyphenols</td>
<td rowspan="5" align="left">Resveratrol</td>
<td align="left">AML -2/DX300</td>
<td align="left">Dox</td>
<td align="left">Inhibiting expression of MRP1</td>
<td align="left">
<xref ref-type="bibr" rid="B91">Li et al. (2018c)</xref>
</td>
</tr>
<tr>
<td align="left">HCT 116</td>
<td align="left">Dox</td>
<td align="left">Inhibition P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B166">Wang et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">K562</td>
<td align="left">Dox</td>
<td align="left">Inhibition of the PI3k/Akt/mTOR pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B78">Khan et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">MCF-7</td>
<td align="left">Dox</td>
<td align="left">Regulation miR-122-5p; Regulation of Bcl-2 and CDKs</td>
<td align="left">
<xref ref-type="bibr" rid="B5">ALkharashi (2023)</xref>
</td>
</tr>
<tr>
<td align="left">Human oral cancer CAR</td>
<td align="left">DDP</td>
<td align="left">Induces expression of mRNA autophagy-related genes, including Beclin-1, Atg5, Atg12, and LC3-II; Enhance phosphorylation of AMPK</td>
<td align="left">
<xref ref-type="bibr" rid="B19">Chang et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">Epigallocatechin-3-gallate</td>
<td align="left">KB-A1</td>
<td align="left">Dox</td>
<td align="left">Inhibition P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B88">Li et al. (2018a)</xref>
</td>
</tr>
<tr>
<td align="left">OVCAR3; SKOV3</td>
<td align="left">DDP</td>
<td align="left">Increasing the expression of CTR1; Inhibiting the degradation of CTR1</td>
<td align="left">
<xref ref-type="bibr" rid="B164">Wang et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">Ovary cancer; NSCLC</td>
<td align="left">DDP</td>
<td align="left">Increasing ROS generation and CTR1 expression; Regulation of ERK1/2/NEAT1 pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B21">Chen et al. (2020a)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Curcumin</td>
<td align="left">A2780cp</td>
<td align="left">DDP</td>
<td align="left">Demethylate in the promoter region of MEG3; Downregulation of miR-214</td>
<td align="left">
<xref ref-type="bibr" rid="B195">Zhou et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">HL-60</td>
<td align="left">Dox</td>
<td align="left">Regulation the HOTAIR/miR-20a-5p/WT1 pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B103">Liu et al. (2021a)</xref>
</td>
</tr>
<tr>
<td align="left">EF24</td>
<td align="left">Ovarian</td>
<td align="left">DDP</td>
<td align="left">Overexpression of p53 and p21 proteins; Induced apoptosis; Activating PTEN phosphorylation inhibiting Akt</td>
<td align="left">
<xref ref-type="bibr" rid="B70">Ib&#xe1;&#xf1;ez Gaspar and McMorrow (2023)</xref>
</td>
</tr>
<tr>
<td align="left">GO-Y030</td>
<td align="left">K562</td>
<td align="left">mitoxantrone</td>
<td align="left">Inhibit BCRP</td>
<td align="left">
<xref ref-type="bibr" rid="B123">Murakami et al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="left">Terpenoid</td>
<td rowspan="4" align="left">&#x3b2;-Elemene</td>
<td align="left">A549</td>
<td align="left">ER</td>
<td align="left">Inhibition P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B98">Lin et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">MCF-7</td>
<td align="left">Dox; Doc</td>
<td align="left">Regulation miRNA29a, miRNA222; Inhibiting the PI3K&#x2013;AKT signaling pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B63">Hu et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">DDP</td>
<td align="left">Decreasing mitochondrial membrane potential and increasing intracellular ROS concentrations</td>
<td align="left">
<xref ref-type="bibr" rid="B99">Liskova et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">SPC-A1</td>
<td align="left">DDP</td>
<td align="left">Promoting Beclin-1</td>
<td align="left">
<xref ref-type="bibr" rid="B92">Li et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Coumarins</td>
<td align="left">PFC</td>
<td align="left">HCT-116</td>
<td align="left">irinotecan</td>
<td align="left">Inhibits BCRP-mediated drug-transport function</td>
<td align="left">
<xref ref-type="bibr" rid="B82">Kokubo et al. (2021)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Dihydromyricetin (DMY), a naturally occurring flavonoid derived from Vitis heyneana, a traditional Chinese medicine plant. By reducing MDR1 mRNA and protein expression to 5-FU cytotoxicity, DMY decreases MRP2 expression and its promoter activity in HCT116/Oxaliplatin (OXA)and HCT8/VCR cells as well as sensitized SGC7901/5-FU cells (<xref ref-type="bibr" rid="B167">Wang et al., 2021</xref>). In order to reestablish chemosensitivity in CRC cells, DMY suppresses the Nrf2/MRP2 signaling pathway (<xref ref-type="bibr" rid="B167">Wang et al., 2021</xref>). DMY also activates p53 and induces apoptosis in paclitaxel (PTX)- and Dox-resistant OvCa cells (<xref ref-type="bibr" rid="B176">Xu et al., 2017</xref>).</p>
<p>Apigenin (API), a common dietary flavonoid, inhibits P-gp and BCRP, increasing cellular uptake of anticancer drugs such as Dox or TXT in MDR (<xref ref-type="bibr" rid="B124">Noorian et al., 2022</xref>). API is reported to suppress cell growth, clonogenicity, and invasiveness in CSCs. In human CD44<sup>&#x2b;</sup> prostate CSCs, API can upregulate caspase-8, apaf-1, and p53 mRNA expression, downregulate Bcl-2, sharpin, and survival, and increase the effectiveness of DDP (<xref ref-type="bibr" rid="B43">Erdogan et al., 2016</xref>; <xref ref-type="bibr" rid="B44">Erdogan et al., 2017</xref>). API suppresses STAT3, Akt, and MAPK in glioblastoma multiforme U87MG and U373MG&#xa0;cells in other CSCs(<xref ref-type="bibr" rid="B79">Kim B. et al., 2016</xref>). A549/OXA/bleomycin (BLM) and H1299/OXA/BLM cells may undergo a large rise in apoptosis as a result of API&#x2019;s ability to activate p53 and pro-apoptotic proteins (<xref ref-type="bibr" rid="B24">Chen et al., 2016</xref>). Acacetin, an O-methylated API, inhibits the MDR1 gene at the mRNA level in NSCLC model cell lines A549/OXA/BLM and H1299/OXA/BLM (<xref ref-type="bibr" rid="B129">Punia et al., 2017</xref>; <xref ref-type="bibr" rid="B145">Singh et al., 2020</xref>).</p>
<p>Wogonin (WOG), a compound known as 5,7-dihydroxy-8-methoxyflavone, is found in fruits, vegetables, and certain medicinal plants. It possesses a wide range of biological activities, including anti-cancer, anti-inflammatory, and the treatment of bacterial and viral infections (<xref ref-type="bibr" rid="B68">Huynh et al., 2020</xref>). By preventing P-gp&#x2019;s expression and functional activity, WOG sensitizes Dox-resistant K562/A02 cells (<xref ref-type="bibr" rid="B175">Xu et al., 2014</xref>). By lowering the expression of HIF-1&#x3b1; in HCT116/DDP cells, WOG suppresses the PI3K/Akt signaling pathway and increases cytotoxicity when combined with medicines like DDP, Dox, and PTX (<xref ref-type="bibr" rid="B58">He et al., 2013</xref>). WOG potentiates apoptosis and inhibits autophagy by regulating AKR1C1/1C2 and TNF-&#x3b1; (<xref ref-type="bibr" rid="B69">Huynh et al., 2017b</xref>). WOG blocks the IGF-1R/AKT signaling pathway in human breast cancer, increasing the cytotoxicity of sorafenib and Dox (<xref ref-type="bibr" rid="B134">Rong et al., 2017</xref>). In human osteosarcoma CSCs with anti-CD133 (<xref ref-type="bibr" rid="B177">Yang et al., 2022</xref>), WOG behavior demonstrate apoptosis through downregulating MMP-9 expression, which inhibits mobility and stops cell renewal (<xref ref-type="bibr" rid="B67">Huynh et al., 2017a</xref>). In response to internal and external stressors brought on by ROS, Nrf2 acts as a transcription factor by up-regulating antioxidant proteins (<xref ref-type="bibr" rid="B86">Leinonen et al., 2014</xref>; <xref ref-type="bibr" rid="B139">Sajadimajd and Khazaei, 2018</xref>). WOG induces ROS accumulation and further sensitizes TRAIL-induced apoptosis in A549 cells (<xref ref-type="bibr" rid="B179">Yang et al., 2013</xref>). Additionally, WOG increases ROS buildup, which increases intracellular ROS, and inhibits Nrf2 nuclear translocation via inactivating NF-&#x3ba;B (<xref ref-type="bibr" rid="B180">Ye et al., 2019</xref>). In DDP-resistant HNC cells, WOG inhibited Nrf2 and glutathione S-transferase P, increasing intracellular ROS (<xref ref-type="bibr" rid="B80">Kim E. H. et al., 2016</xref>).</p>
<p>Kaempferol (KAE), 3,4&#x2032;,5,7-tetrahydroxyflavone, is a secondary metabolite found in many plants, and traditional medicines. KAE can inhibit ABCB1/P-gp through enhancing the capacity of ATPase (<xref ref-type="bibr" rid="B46">Felice et al., 2022</xref>), and also as an ABCG2/BCRP substrate, it can inhibit ABCG2/BCRP upregulation. KAE appears to have potential synergies with DDP, inhibits the mRNA levels of MRPs and cMyc in OVCAR-3 cells (<xref ref-type="bibr" rid="B7">Amjad et al., 2022</xref>). KAE promotes the development of miR-326, suppresses the process of glycolysis, and the resistence of HCT8-R cells to 5-Fluorouracil (5-FU) (<xref ref-type="bibr" rid="B169">Wu et al., 2022</xref>). KAE may increase the capacity of chronic myeloid leukemia (CML) cells to withstand the pro-apoptotic effects of anti-TRAIL antibodies (<xref ref-type="bibr" rid="B141">Saraei et al., 2022</xref>). Additionally, in human LS174-R colon cancer cells that are resistant to 5-FU, KAE suppresses reactive oxygen species and modifies the expression of JAK/STAT3, MAPK, PI3K/AKT, and NF-&#x3ba;B (<xref ref-type="bibr" rid="B132">Riahi-Chebbi et al., 2019</xref>).</p>
<p>Quercetin can be found in numerous fruits such as apples, berries (such as blueberries and cranberries), citrus fruits (such as oranges and lemons), and grapes. It is also present in vegetables such as onions, broccoli, kale, and tomatoes. Additionally, quercetin can be found in leaves of plants such as tea leaves and grains like buckwheat. In 5-FU-resistant BEL/5-FU cells, QUE would prevent ABCB1/P-gp and MRPs from functioning and expressing (<xref ref-type="bibr" rid="B30">Chen et al., 2018</xref>). Dox, PTX, VCR, and QUE combined treatment substantially reduces ABCB1/P-gp expression and eliminates breast CSCs (<xref ref-type="bibr" rid="B91">Li S. et al., 2018</xref>). Additionally, quercetin suppresses colorectal and breast CSCs (<xref ref-type="bibr" rid="B12">Azizi et al., 2022</xref>). QUE can control HIF-1&#x3b1;, which re-sensitizes 4T1 cells, MCF-7/Dox cells, and HCT116 cancer cells to DDP and etoposide (<xref ref-type="bibr" rid="B81">Kim et al., 2012</xref>). Through the miR-217-KRAS axis, QUE boosts osteosarcoma 143B cells&#x2019; sensitivity to the chemotherapy drug DDP (<xref ref-type="bibr" rid="B191">Zhang X. et al., 2015</xref>).</p>
<p>Collateral sensitivity (CS) involves the exploration of medications that specifically induce a higher level of cytotoxicity in MDR cells compared to the original non-resistant cells (<xref ref-type="bibr" rid="B40">Efferth et al., 2020</xref>). Galangin (GA), which has been extracted from the root of <italic>Alpinia galanga</italic>, has greater inhibitory effects on MDR cells (<xref ref-type="bibr" rid="B108">Lorendeau et al., 2014</xref>), and demonstrates collateral sensitivity (<xref ref-type="bibr" rid="B109">Lorendeau et al., 2017</xref>). A study found that GA increased the p53-dependent apoptotic pathway in ovarian cancer cells A2780/CP70/DDP and OVCAR-3/DDP, favorably inducing apoptosis compared to normal ovarian cells (<xref ref-type="bibr" rid="B65">Huang et al., 2020</xref>). GA through inactivating p-STAT3/p65 and Bcl-2 pathways attenuates DDP-induced resistance in A549 cells (<xref ref-type="bibr" rid="B184">Yu et al., 2018</xref>).</p>
<p>An isoflavone called puerarin (PU) was isolated from the plant <italic>Pueraria lobata (Willd.) Ohwi</italic>. There is a study by Li et al. which shows that PU suppresses Akt and JNK phosphorylation and promotes death in K562/Dox cells, as well as that autophagy makes tumor cells more resistant to anticancer drugs (<xref ref-type="bibr" rid="B104">Liu Q. et al., 2021</xref>). By inhibiting the NF-&#x3ba;B pathway and reducing MDR1 expression, PU sensitized K562/Dox cells (<xref ref-type="bibr" rid="B104">Liu Q. et al., 2021</xref>).</p>
<p>The primary daidzein metabolites genistein (IFG) and 7,3&#x2032;,4&#x2032;-trihydroxyisoflavone (TDI), which are present in fruits, nuts, and soy, also exhibit anti-Nrf2 and anti-ROS properties. The degree of methylation in the Keep1 promoter region is controlled by IFG, which decreases nucleus transcription and raises ROS in A549 cells (<xref ref-type="bibr" rid="B34">Cort et al., 2016</xref>; <xref ref-type="bibr" rid="B106">Liu et al., 2016</xref>). IFG and radiation are both effective in increasing cell apoptosis in A549 cells. TDI downregulation of ABCB1/P-gp and MRPs leads to a significant increase in EPI accumulation and attenuation of EPI resistance in HeLa cells (<xref ref-type="bibr" rid="B66">Hummelova et al., 2015</xref>). The methylation of some cancer-related genes may be hijacked by cancer cells to promote tumorigenesis. Research shows that IFG (0.5&#x2013;10&#xa0;&#x3bc;M) may lower the level of methyl DNA transference (MNDF). IFG (0.5&#x2013;10&#xa0;&#x3bc;M) significantly decreased the methylation of the Estrogen receptor &#x3b2; (ER-&#x3b2;) promoter in prostate cancer (PCa), ER-&#x3b2; which has an inducing effect on PCa cellular metabolism (<xref ref-type="bibr" rid="B74">Ji et al., 2022</xref>). IFG regulates caspase-3 and p38MAPK pathways and induces apoptosis in PC3 prostate cancer cells (<xref ref-type="bibr" rid="B147">Song et al., 2020</xref>).</p>
<p>Luteolin (LU), 3&#x2032;,4&#x2032;,5,7-Tetrahydroxyflavone, is a compound that is abundantly found in leaves and aromatic flowering plants. It possesses anti-inflammation, anti-allergy, and anti-cancer properties, and can function as either an antioxidant or a pro-oxidant biochemically (<xref ref-type="bibr" rid="B107">Lo et al., 2012</xref>). Additionally, LU has the power to dramatically decrease Nrf2 and enhance the cytotoxicity of DDP in KKU-100 cholangiocarcinoma cells; HCT116/OXA and SW620/OXA cells; A549/BLM/Dox cells and in MDA-MB 231/Dox cells. By increasing the expression of the epithelial biomarker E-cadherin, LU can reverse EMT. It also suppresses Hif-1&#x3b1; signaling in cervical cancer cell lines to prevent the invasivity from being activated (<xref ref-type="bibr" rid="B71">Imran et al., 2019</xref>). In pancreatic cancer cells, LU induces apoptosis by blocking the K-RAS/GSK-3&#x3b2;/NF-&#x3ba;B signaling pathway (<xref ref-type="bibr" rid="B71">Imran et al., 2019</xref>).</p>
<p>Honey, propolis, and the passion flower Passiflora caerulea all contain chrysin, which is a 5,7-dihydroxyflavone. Chrysin has the power to stop the efflux of ABCB1/P-gp from MDA-MB-231/mitoxantrone cells and regulate the transport of nitrofurantoin through ABCG2/BCRP from BCRP-overexpressing MCF-7 cells. Moreover, chromatin sensitizes BCRP-transfected cells via stimulating ATPase (<xref ref-type="bibr" rid="B4">Ahmed-Belkacem et al., 2005</xref>).</p>
<p>Due to the pseudo-dimeric shape of ABC transporters, Synthetic compounds were synthesized from natural flavonoids using a &#x201c;click chemistry&#x201d; method to efficiently produce a variety of triazole-bridged homo- and heteroflavonoid dimers. Ac15(Az8)2, a flavonoid dimer, inhibits BCRP potently, safely, and specifically. Through the inhibition of BCRP-ATPase activity and drug efflux in S1M180/topotecan cells, Ac15(Az8)2 restored intracellular drug accumulation, according to mechanistic investigations (<xref ref-type="bibr" rid="B32">Chong et al., 2022</xref>).</p>
</sec>
<sec id="s3-2">
<title>3.2 Alkaloids</title>
<p>Alkaloids are also secondary metabolites that are found in a variety of plants, fungi, and bacteria worldwide. The presence of one or more basic nitrogens, often in a heterocyclic ring, and significant pharmacological activity characterize an alkaloid. Their P-gp inhibitory function is likewise influenced by the basic nitrogen atoms (<xref ref-type="bibr" rid="B54">Gon&#xe7;alves et al., 2020</xref>) (<xref ref-type="fig" rid="F3">Figure 3</xref>; <xref ref-type="table" rid="T1">Table 1</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Chemical structures of Alkaloids, Polyphenols, Terpenoids and Coumarins having MDR modulatory activity.</p>
</caption>
<graphic xlink:href="fphar-15-1348076-g003.tif"/>
</fig>
<p>Lycorine (LYC) is a commonly used alkaloids extracted from the bulb of Lycoris radiate, recognized for its various biological effects, which include anticancer, antiviral, antibacterial, and anti-inflammatory activities (<xref ref-type="bibr" rid="B135">Roy et al., 2018</xref>). TCRP1 is a new candidate for a human gene that is associated with chemotherapeutic resistance. It is expressed extensively in various types of cancer cells and is associated with chemotherapeutic resistance (<xref ref-type="bibr" rid="B105">Liu X. et al., 2019</xref>). LYC lowers the levels of tongue cancer and Hepatocellular Carcinoma (HCC) cells TCRP1 protein by promoting the degradation pathway of TCRP1 protein, which translates into repression of Akt/mTOR signaling, and therefore activates apoptotic and autophagic abilities (<xref ref-type="bibr" rid="B182">Yu H. et al., 2017</xref>). Bioinformatics analysis revealed that upregulation of FABP5 expression facilitates acute myeloid leukemia (AML) cell viability, protects AML cells from apoptosis. LYC downregulated the expression levels of FABP5 and its target PPAR&#x3b3;, impaired AML cell viability, and triggered apoptosis (<xref ref-type="bibr" rid="B96">Liang et al., 2023</xref>). By performing extracellular, cytoplasmic, and nuclear roles, HMGB1 is crucial for stress signaling as well as for the activation of autophagy. Because autophagy is inhibited in human bone marrow CD138 primary myeloma cells and multiple myeloma (MM) cell lines, LYC-induced proteasomal degradation of HMGB1 inhibits the activation of the MEK-ERK signaling pathway and Bcl-2 phosphorylation declines, leading to the constitutive association of Bcl-2 with Beclin-1 (<xref ref-type="bibr" rid="B136">Roy et al., 2016</xref>). LYC inhibits EGF-induced JAK/STAT signaling as well as various downstream STAT3 targets, such as cyclin D1, Bcl-2, Bcl-xL, matrix metalloproteinase 2 (MMP2), and the EMT promoter Twist, which lowers prostate cancer cell line proliferation, migration, invasion (<xref ref-type="bibr" rid="B62">Hu et al., 2015</xref>). Amaryllidaceae alkaloids were investigated as MDR reversibles in human colon cancer cells by derivatizing alkaloid hydroxyl groups into mono- and di-carbamates. Di-carbamates that contain phenethyl or benzyl moieties were found to be more potent inhibitors than verapamil. The collateral sensitivity of a number of derivatives also suggested a dual role in reversing P-gp-mediated MDR (<xref ref-type="bibr" rid="B140">Sancha et al., 2023</xref>).</p>
<p>Securinega alkaloids (SA) are indolizidine alkaloids derived from the Asian plant <italic>Securinega suffruticosa</italic>&#x2019;s leaf and root. SA Several activities have been documented, including antiproliferative activity, leukemia differentiation induction activity, MDR reversal activity, antimalarial activity, and antibacterial activity (<xref ref-type="bibr" rid="B61">Hou et al., 2023</xref>). Recent studies have found altering securinine at the C15 sites increases the ability to reverse drug resistance caused by several drugs, whereas derivatives with a bivalent mimic attached to the C15 site increase the ability to induce differentiation and reverse drug resistance caused by P-gp. Mechanism investigations indicated MDR reversal action in HepG2/Doxvia reduction of P-gp function against Dox (<xref ref-type="bibr" rid="B61">Hou et al., 2023</xref>).</p>
<p>The bisbenzyl isoquinoline alkaloid tetrandrine (TET), which was isolated from the Chinese plant <italic>Stephania tetrandra</italic> (Han-Fang-Chi), has anticancer effects because it inhibits cell proliferation and induces apoptosis (<xref ref-type="bibr" rid="B197">Zhou et al., 2022b</xref>). Previous research has shown that TET and its derivatives can reverse MDR caused by osteosarcoma/Dox. TET may significantly increase intracellular chemotherapeutic drug concentration by changing the expression of the MDR1 gene and P-gp, and can be used in combination with chemotherapy drugs to significantly inhibit P-gp expression (<xref ref-type="bibr" rid="B197">Zhou et al., 2022b</xref>). TET inhibits drug efflux caused by MDR1 overexpression and has anti-MDR action in Hep-2/VCR cells (<xref ref-type="bibr" rid="B93">Li Y. et al., 2020</xref>). TET decreased transporter protein mRNA and protein levels suppress MRP overexpression in MDR human esophageal squamous carcinoma YES-2/DDP cells and epidermis-like k2&#x2013;mrp1 cancer cells (<xref ref-type="bibr" rid="B162">Wang et al., 2018</xref>). Molecular dynamics simulations were employed to design OY-101, a novel chemical compound derived from the modification of natural TET. OY-101 demonstrated selective and potent inhibition of P-gp (<xref ref-type="bibr" rid="B185">Zeng et al., 2023</xref>). Fangchinoline (FAN) is a prominent bisbenzylisoquinoline (BBIQ) alkaloid derived from the roots of <italic>S. tetrandra</italic> in the Menispermaceae family that consists of two benzylisoquinoline units joined by oxygen bridges. FAN has been shown to reverse MDR in Caco-2 and CEM/Dox5000 cancer cells when combined with Dox (<xref ref-type="bibr" rid="B18">Chan et al., 2021</xref>).</p>
<p>Oxymatrine (OMA) and matrine (MA), as natural compounds derived from <italic>Sophora flavescens</italic>, have been reported to possess a wide range of pharmacological properties, including anti-inflammatory, antiviral, anti-tumor, and immunomodulatory effects. In addition to considerably reversing cellular MDR, enhancing apoptotic induction, suppressing MRP1 expression, and inactivating NF-&#x3ba;B signaling by lowering phosphorylated p65, OMA alone or in conjunction with 5-FU significantly reversed cellular MDR (<xref ref-type="bibr" rid="B39">Du and Shim, 2016</xref>). One of the signaling pathways responsible for 5-FU resistance in CRC is NF &#x3ba;B. Combining OMA and OXA improved both the <italic>in vitro</italic> and <italic>in vivo</italic> anticancer effects of OXA in CRC cancer cells. These additive effects were attained by suppressing the NF &#x3ba;B and PI3K/AKT/mTOR signaling pathways, which decreased the treatment resistance of CRC cancer cells. OMA is known to inhibit the NF &#x3ba;B pathway, so its combination with OXA could provide an enhanced therapeutic benefit (<xref ref-type="bibr" rid="B25">Chen M. H. et al., 2021</xref>). LRP, or lung resistance protein, is a cytoplasmic vault protein that plays a role in both the vesicular sequestration of drugs in the cytoplasm and their translocation from the nucleus to the cytoplasm. MA reversed drug resistance in OXA-resistant HT-29/OXA cells, increased HT-29/OXA cells&#x2019; sensitivity to OXA in a dose-dependent manner, and significantly decreased LRP and P-gp expression in HT-29/OXA cells at the mRNA and protein levels. In K562/Dox cells, MA causes a dose-dependent stoppage of the cell cycle at the G0/G1 phase, which promotes autophagy (<xref ref-type="bibr" rid="B95">Li Z. et al., 2020</xref>).</p>
<p>Rutaecarpine (Rut), a bioactive alkaloid found in <italic>Evodia rutaecarpa</italic>, has been associated with various pharmacological effects such as analgesic, anticancer, and anti-inflammatory properties. On P-gp-overexpressing MCF-7/Dox and A549/PTX cells, Rut dose-dependently improved the effectiveness of Dox, PTX, and colchicine. Since the ubiquitination pathway plays a major role in protein degradation, the E3 ubiquitin ligase MARCH8 is an ABCB1/P-gp substrate. MARCH8 interacts with ABCB1/P-gp to promote ubiquitination and degradation (<xref ref-type="bibr" rid="B189">Zhang et al., 2023</xref>). Rut can boost MARCH8 expression, which encourages the degradation of ABCB1/P-gp (<xref ref-type="bibr" rid="B198">Zou et al., 2021</xref>). Castration-resistant prostate cancer (CRPC) is largely brought on by androgen receptor splice variation 7 (AR-V7). Rut restores the susceptibility of castration-resistant prostate cancer to anti-androgen therapy <italic>in vitro</italic> and <italic>in vivo</italic> by specifically inducing AR-V7 protein degradation via K48-linked ubiquitination (<xref ref-type="bibr" rid="B97">Liao et al., 2020</xref>).</p>
<p>A bisindole alkaloid known as voacamine (VOA) was discovered in the <italic>Voacanga</italic> and <italic>Peschiera</italic> species of the Apocynaceae family. VOA possesses a variety of biological qualities, including antibacterial action, resistance to Plasmodium falciparum, strong neuroprotective activity against Alzheimer&#x2019;s disease, and the ability to inhibit the mutagenicity brought on by several genotoxic substances (<xref ref-type="bibr" rid="B155">Theissinger et al., 2023</xref>). VOA was an effective substrate for P-gp and acted as a competitive antagonist to obstruct P-gp-mediated drug export. When VOA was administered to U-2 OS-DX/Dox cells, laser scanning confocal microscopy (LSCM) studies showed a disorganizing effect on microtubules (<xref ref-type="bibr" rid="B33">Condello et al., 2020</xref>).</p>
</sec>
<sec id="s3-3">
<title>3.3 Polyphenols</title>
<p>A massive family of 10,000 plant compounds known as polyphenols is mostly present in fruits, green and black tea, coffee, red wine, chocolate, and seeds (<xref ref-type="bibr" rid="B192">Zhang Y. et al., 2022</xref>). Polyphenols frequently have three-membered flavan ring structures. In the body, free radicals primarily fall into two categories: ROS and reactive nitrogen species (RNS). The involvement of the B rings in scavenging ROS/RNS and the capacity of hydroxyl groups connected to benzene rings to donate a hydrogen atom or an electron to free radicals are essential elements of the mechanism underpinning polyphenol action. Cell death, EMT, ROS, DNA repair procedures, CSCs, and epigenetics [such as MicroRNAs (miRNAs)] are some other targets that polyphenols affect in order to combat chemoresistance in cancer cells (<xref ref-type="bibr" rid="B163">Wang et al., 2022</xref>) (<xref ref-type="fig" rid="F3">Figure 3</xref>; <xref ref-type="table" rid="T1">Table 1</xref>).</p>
<p>Numerous cancers, including bladder, prostate, breast, lung, glioblastoma, colon, and ovarian, are affected by resveratrol (RES) in terms of apoptosis (<xref ref-type="bibr" rid="B131">Ren et al., 2021</xref>). Under the regulation of MRP1, various endogenous and xenobiotic substrates are absorbed and eliminated. Due to the elevated levels of MRP1 gene expression in Dox-resistant acute myeloid leukemia (AML)-2/DX300 cells, its expression may lead to a decrease in drug cellular absorption (<xref ref-type="bibr" rid="B23">Chen J. et al., 2019</xref>). RES with Dox decreases Dox IC50 from 0.96 &#xb1; 0.02&#xa0;M to 0.52 &#xb1; 0.05&#xa0;M in HCT 116 colorectal cancer cells, increases Dox intracellularly, and inhibits the efflux action of P-gp (<xref ref-type="bibr" rid="B166">Wang et al., 2020</xref>). Inhibitory the PI3K/Akt/mTOR pathway causes the inhibitory impact of RES over P-gp in K562/Dox cells (<xref ref-type="bibr" rid="B78">Khan et al., 2020</xref>). RES recognize miR-122-5p and regulates Bcl-2 and CDKs, resulting in the chemosensitization of Dox-resistant breast cancer MCF-7 cells (<xref ref-type="bibr" rid="B5">ALkharashi, 2023</xref>). In DDP-resistant human oral cancer CAR cells, RES therapy promotes the expression of autophagy-related genes, such as Beclin-1 Atg12 and LC3-II, at the mRNA level and increases AMPK phosphorylation. This results in regulated autophagy and pro-apoptosis-related signals to be send (<xref ref-type="bibr" rid="B19">Chang et al., 2017</xref>). RES dramatically reduced the activation of tumor-promoting factors (NF-&#x3ba;B, MMP-9, CXCR4) and epithelial-to-mesenchymal transition-factors (increased vimentin and slug, decreased E-cadherin) in TNF-induced activation of CRC cells by preventing EMT and CSC formation (<xref ref-type="bibr" rid="B16">Buhrmann et al., 2018</xref>). RES treatment results in elevated levels of DNA topoisomerase-II (TOPO), an enzyme that is commonly found in malignancies and plays a crucial role in maintaining DNA structure during transcription and DNA replication. Furthermore, the RES-treated group exhibited significantly higher levels of Topo-II compared to other groups. It appears that RES promotes drug-induced DNA damage in Dox-resistant PUMC-91/Dox cells (<xref ref-type="bibr" rid="B146">Skok et al., 2020</xref>; <xref ref-type="bibr" rid="B31">Choi et al., 2022</xref>). 5-FU resistant (5-FU-R) cells may exhibit resistance to the DNA-damaging chemical 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). However, when RES and BCNU are combined, it is enhance the sensitivity and induce DNA damage in 5-FU-R cells (<xref ref-type="bibr" rid="B31">Choi et al., 2022</xref>).</p>
<p>A significant polyphenolic component of green tea called epigallocatechin-3-gallate (EGCG) has several beneficial properties, including the capacity to lower stress, regulate metabolism, prevent cancer, and offer protection from various diseases. In drug-resistant KB-A1 cells, EGCG has been found to alter P-gp activity and increase intracellular Dox concentration (<xref ref-type="bibr" rid="B153">Tang et al., 2017</xref>; <xref ref-type="bibr" rid="B88">Li H. et al., 2018</xref>). The primary copper influx transporter CTR1 is in charge of copper&#x2019;s resistance to platinum. Because EGCG raises CTR1 expression at the mRNA and protein levels in ovarian cancer cells and upregulates the rapid DDP-induced degradation of CTR1, OVCAR3 and SKOV3 ovarian cancer cells are more vulnerable to DDP when it is present (<xref ref-type="bibr" rid="B164">Wang et al., 2015</xref>). Ovarian cancer and non-small-cell lung cancer (NSCLC) cells were made more susceptible to DDP when supplemented with EGCG by increasing ROS generation and CTR1 expression through activating the ERK1/2/NEAT1 pathway (<xref ref-type="bibr" rid="B21">Chen A. et al., 2020</xref>). Through suppression of the Bcr/Abl oncoprotein and control of its downstream p38-MAPK/JNK and JAK2/STAT3/AKT pathways, EGCG was able to decrease cell proliferation and cause apoptosis in CML (<xref ref-type="bibr" rid="B172">Xiao et al., 2019</xref>). The DDP-induced DNA damage is substantially repaired by the 5&#x2032;-3&#x2032; structure-specific endonuclease ERCC1/XPF. A DNA-endonuclease incision test based on fluorescence was used to identify (<xref ref-type="bibr" rid="B60">Heyza et al., 2018</xref>). EGCG exhibits inhibitory effects on colorectal CSCs and lung CSCs. It downregulates the activation of the Wnt/&#x3b2;-catenin pathway (<xref ref-type="bibr" rid="B28">Chen et al., 2017</xref>; <xref ref-type="bibr" rid="B49">Fujiki et al., 2018</xref>).</p>
<p>Curcumin (Cur) is an active polyphenolic pigment obtained from the rhizomes of <italic>Curcuma longa</italic>. Cur is typically used for its antioxidant, anti-inflammatory, wound-healing, and anti-carcinogenesis qualities that halt the onset or progression of cancer (<xref ref-type="bibr" rid="B157">Tomeh et al., 2019</xref>). The inhibition of ABC family transporters by Cur in various cancer cells causes drug accumulation within cancer cells (<xref ref-type="bibr" rid="B38">Dong et al., 2023</xref>). Cur is a helpful medicine when used in conjunction with significant chemotherapeutic medications to combat MDR. Cur causes DNA damage in several cell lines and inhibits particular DNA repair enzymes. Rad51-dependent homologous recombination is a crucial DNA repair pathway that enables cancer cells to develop resistance to medications that target tumor DNA damage. However, Cur has been found to lower the expression of Rad51, leading to DNA damage in cancer cells (<xref ref-type="bibr" rid="B193">Zhao et al., 2018</xref>; <xref ref-type="bibr" rid="B168">Wong, 2021</xref>). According to reports, Cur is a powerful DNA hypomethylation agent that inhibits DNMT1 activity by covalently attaching to and inhibiting the catalytic thiol group of cysteine (C1226) (<xref ref-type="bibr" rid="B170">Wu et al., 2016</xref>; <xref ref-type="bibr" rid="B158">Tong et al., 2020</xref>). By preventing the expression of DNMT1, Cur slows down cell growth and triggers apoptosis in hepatocellular carcinoma (<xref ref-type="bibr" rid="B102">Liu et al., 2017</xref>). Numerous varieties of multidrug resistant cancer cells were revealed to have improper NF-&#x3ba;B regulation. The expression of genes regulated by NF-&#x3ba;B is decreased as a result of Cur&#x2019;s suppression of NF-&#x3ba;B activity and prevention of NF-&#x3ba;B binding to DNA (<xref ref-type="bibr" rid="B195">Zhou et al., 2017</xref>). Cur reduces I&#x3ba;B&#x3b1; kinase activity in human head and neck squamous cell carcinoma cell lines, which blocks NF-&#x3ba;B activity. By blocking the PI3K/AKT pathway, which reduces NF-&#x3ba;B expression, Cur increases the sensitivity of cancer cells to treatment (<xref ref-type="bibr" rid="B121">Mortezaee et al., 2019a</xref>; <xref ref-type="bibr" rid="B159">Villegas et al., 2021</xref>; <xref ref-type="bibr" rid="B1">Abadi et al., 2022</xref>). Cur may demethylate in the MEG3 promoter area in the A2780cp ovarian cancer cell line, which downregulates miR-214 and, indirectly, lowers DDP resistance (<xref ref-type="bibr" rid="B195">Zhou et al., 2017</xref>). Liu et al. proposed a potential regulatory network involving HOX transcript antisense RNA (HOTAIR), miR-20a-5p, and Wilms&#x2019; tumor 1 (WT1). Their findings demonstrated that Cur inhibits the levels of WT1 in human acute myeloid leukemia cells (HL-60) or HL-60/Dox cells. They also observed that the suppression of miR-20a-5p, resulting in increased WT1 expression, attenuated the effect of Cur on the resistance of leukemia cells to Dox. These results indicate that Cur inhibits the resistance of tumor cells to Dox by targeting the HOTAIR/miR-20a-5p/WT1 axis. Cur slows the proliferation of cancer cells, as evidenced by the downregulation of NF-&#x3ba;B in mantle cell lymphoma, oral MCF-7, and non-small-cell lung carcinoma (<xref ref-type="bibr" rid="B117">Meiyanto et al., 2014</xref>). Additionally, the activation of redox processes within cells leads to the generation of ROS, which upregulates the apoptotic receptors on the membrane of tumor cells (<xref ref-type="bibr" rid="B122">Mortezaee et al., 2019b</xref>). Cur decreases tumor cell growth and increases apoptosis by upregulating the expression and activity of p53, attenuating the regulation of antiapoptosis PI3K signaling and MAPKs to boost endogenous ROS generation, and overexpressing antiapoptosis genes such Bcl-2 (<xref ref-type="bibr" rid="B122">Mortezaee et al., 2019b</xref>). By controlling oxidative stress, modulating fibrosis, activating SIRT1, and encouraging cellular apoptosis, Cur may kill MCF7/TH, HCT116R, and A549/Dox cancer cells (<xref ref-type="bibr" rid="B50">Gabr et al., 2022</xref>). A therapeutic target, nicotinamide N-methyltransferase (NNMT) has a variety of effects on CRC aggressiveness and 5-FU resistance (<xref ref-type="bibr" rid="B1">Abadi et al., 2022</xref>). Cur has the ability to reduce NNMT and p-STAT3 expression. Particularly in CRC cell lines with significant NNMT expression, Cur may also lessen ROS generation, G2/M phase cell cycle arrest, and cell growth (<xref ref-type="bibr" rid="B77">Keyvani-Ghamsari et al., 2020</xref>; <xref ref-type="bibr" rid="B50">Gabr et al., 2022</xref>).</p>
<p>Cur plays a wide range of roles in cancer cells&#x2019; multidrug resistance, but its clinical application is challenging. Cur&#x2019;s weak solubility, minimal absorption, restricted tissue distribution, and quick metabolism are its significant drawbacks. Generating novel Cur analogues is one method to solve these issues. EF24 is a developed Cur analog. By suppressing NF-&#x3ba;B, HIF-1&#x3b1;, controlling the creation of ROS, and controlling important genes by miRNA, EF24 prevented cancer cells from going through the cell cycle and caused apoptosis (<xref ref-type="bibr" rid="B14">Bisht et al., 2016</xref>; <xref ref-type="bibr" rid="B70">Ib&#xe1;&#xf1;ez Gaspar and McMorrow, 2023</xref>). EF24 makes ovarian cancer resistant cells more susceptible to DDP by causing an overexpression of the p53 and p21 proteins in the G2/M checkpoint. In DDP-resistant cells, it also induces apoptosis by promoting PTEN phosphorylation and inhibiting Akt, a resistance cell (<xref ref-type="bibr" rid="B148">Su et al., 2023</xref>). Go-Y030, EF24 analog of Cur, can stop K562/mitoxantrone cells from producing mitoxantrone and pheophorbide A from ABCG2/BCRP (<xref ref-type="bibr" rid="B123">Murakami et al., 2017</xref>). Another Cur homologue with better bioavailability is CDF. Pancreatic cancer cells underwent apoptosis and had their NF-&#x3ba;B activity inhibited when CDF and gemcitabine were combined (<xref ref-type="bibr" rid="B85">Lee et al., 2018</xref>). Additionally, PTEN expression was increased while overexpressed miR-21 expression was decreased by CDF, which prevented cells resistant to gemcitabine from undergoing cellular arrest (<xref ref-type="bibr" rid="B85">Lee et al., 2018</xref>). The androgen receptor (AR) in prostate cancer has been reported to promote treatment resistance. <italic>In vitro</italic> and <italic>in vivo</italic>, a Cur analog named ALZ003 significantly lowers the survival of TMZ-sensitive and -resistant glioblastoma by triggering FBXL2-mediated AR ubiquitination, which leads to its degredation (<xref ref-type="bibr" rid="B15">Bott et al., 2016</xref>; <xref ref-type="bibr" rid="B26">Chen T. C. et al., 2020</xref>).</p>
</sec>
<sec id="s3-4">
<title>3.4 Terpenoids and Coumarins</title>
<sec id="s3-4-1">
<title>3.4.1 Terpenoids</title>
<p>Terpenoid is a class of natural compounds that is both extensively studied and structurally diverse. Terpenoids are classified into monoterpenoids (C10), sesquiterpenoids (C15), diterpenoids (C20), sesterterpenoids (C25), triterpenoids (C30), tetraterpenes (C40), and polyterpenes based on the number of isoprene units present in the parent structure. Terpenoids display numerous medicinal benefits, such as hypoglycemia, liver protection, antibacterial, anti-inflammatory, and anti-tumor characteristics (<xref ref-type="bibr" rid="B84">Kumar and Jaitak, 2019</xref>) (<xref ref-type="fig" rid="F3">Figure 3</xref>; <xref ref-type="table" rid="T1">Table 1</xref>).</p>
<p>The sesquiterpene chemical &#x3b2;-Elemene (&#x3b2;-ELE), derived from <italic>Curcuma Rhizoma</italic>, exhibits properties such as inhibiting cell proliferation, arresting the cell cycle, inducing cell death, and reversing MDR in chemotherapy. &#x3b2;-ELE may be able to overcome drug resistance in human NSCLC A549/ER cells that are resistant to erlotinib (ER) <italic>in vitro</italic> by lowering P-gp expression, suppressing P-gp dependent drug efflux, and increasing intracellular concentrations of anticancer drugs (<xref ref-type="bibr" rid="B98">Lin et al., 2018</xref>). MiRNAs found in exosomes, function in the mechanism of intercellular communication and modify chemosensitivity. The intercellular transfer of certain miRNAs is partly responsible for the MDR of tumor cells. The ability of MDR Breast Cancer Anti-Estrogen (BCA) cells to propagate drug resistance is determined by the exosomes they produce. Recent research has demonstrated that &#x3b2;-ELE influences exosome content, affects the expression of certain MDR-related miRNAs, and reduces the exosome-mediated transmission of drug resistance, thereby enhancing the cells&#x2019; capacity to overcome MDR (<xref ref-type="bibr" rid="B186">Zhang J. et al., 2015</xref>). In the exosomes of multidrug-resistant gastric cancer cells, miR-1323 is significantly expressed, which encourages EMT of gastric cancer sensitive cells and enhances their capacity for invasion and migration (<xref ref-type="bibr" rid="B152">Tan et al., 2021</xref>). The expression of Cbl-b is likewise suppressed by miR-1323, resulting in the attenuation of drug resistance in cancer cells with MDR. By reversing the drug resistance and metastasis generated by exosomes, &#x3b2;-ELE reduces the ability of SGC7901 cells to resist drugs and migration (<xref ref-type="bibr" rid="B152">Tan et al., 2021</xref>). In terms of internal miRNA-29a and miRNA222, human MCF-7 cells that were resistant to Docetaxel (MCF-7/Doc) and Dox (MCF-7/Dox), respectively, were significantly downregulated by &#x3b2;-ELE. The tumor cells&#x2019; medication resistance was overcome by suppression of the PI3K-AKT signaling pathway. PTEN, a common tumor suppressor gene that blocks the PI3K-AKT signaling pathway, is the two miRNAs&#x2019; target gene and is significantly increased after miRNA-29a and miRNA222 are downregulated (<xref ref-type="bibr" rid="B63">Hu et al., 2019</xref>). A549/DDP cells underwent apoptosis when exposed to &#x3b2;-ELE because it decreased the mitochondrial membrane potential and increased intracellular ROS levels which may cause apoptosis and mitochondrial damage (<xref ref-type="bibr" rid="B99">Liskova et al., 2021</xref>) By increasing Caspase-3 protein expression, &#x3b2;-ELE may be used to overcome gastric cancer resistance (<xref ref-type="bibr" rid="B110">Low et al., 2021</xref>). &#x3b2;-ELE can additionally reduce chemoresistance in lung cancer by inhibiting the paracrine activities mediated by cyclin-dependent kinase inhibitor P21, which are regulated by CDK8. SPC-A1/DDP, a DDP-resistant lung cancer cell line, is more susceptible to apoptosis and medication treatment when &#x3b2;-ELE which is accomplished via fostering Beclin-1-induced autophagy (<xref ref-type="bibr" rid="B92">Li et al., 2021</xref>).</p>
<p>PU-1 is a sesquiterpene with the &#x3b1;-methylene-&#x3b3;-lactone moiety that has been isolated from numerous plant species of the genera Inula and the genus Pulicaria. It might have anti-inflammatory and anti-cancer effects. In CCRF-CEM leukemic cells, the PI3K/AKT pathway prevents the development of drug-resistant tumor cells by causing DNA damage, obstructing the G2/M cell cycle, and triggering apoptosis. Resazurin reduction tests showed that PU-1 suppressed this pathway (<xref ref-type="bibr" rid="B59">Hegazy et al., 2021</xref>).</p>
</sec>
<sec id="s3-4-2">
<title>3.4.2 Coumarins</title>
<p>Coumarins are a class of organic compounds that are widely distributed in nature, including in plants such as fruits, vegetables, and herbs. They are characterized by a benzene ring fused to an alpha-pyrone ring. The phenylfurocoumarin derivative (R)-9-(3,4-dimethoxyphenyl)-4-((3,3-dimethyloxiran-2-yl)methoxy)-7H-furo [3,2-g]chromen-7-one (PFC) in HCT-116/BCRP colon cancer cells, drastically lowers the IC50 of SN-38 while inhibiting ABCG2/BCRP-mediated drug transport function. Additionally, in the ABCG2/BCRP-overexpressing HCT-116/BCRP cell xenograft mice model, PD-stimulated ABCG2/BCRP-mediated ATP hydrolysis reduced irinotecan resistance without resulting in toxicity (<xref ref-type="bibr" rid="B82">Kokubo et al., 2021</xref>). In a recent study, fifteen sesquiterpene coumarins were extracted and purified from various Ferula species and tested for their ability to reverse MDR. The study found that the sesquiterpene coumarins enhanced Dox cytotoxicity in MCF-7/Dox cells, which are Dox-resistant derivatives of MCF-7 cells that overexpress the P-gp protein. Further analysis of the structure-activity relationship of these sesquiterpene coumarins indicated that ring-opened drimane-type compounds, specifically farnesiferol B, farnesiferol C, and lehmferin, exhibited the most potent inhibitory effects on P-gp pump efflux. These compounds could be considered as lead scaffolds for future modifications to improve their efficacy in reversing MDR (<xref ref-type="bibr" rid="B76">Kasaian et al., 2015</xref>) (<xref ref-type="fig" rid="F3">Figure 3</xref>; <xref ref-type="table" rid="T1">Table 1</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>4 Conclusion</title>
<p>Drug resistance is usually the reason why cancer treatments fail, despite major advancements in the manufacturing of new chemotherapeutic medications. Researchers have started taking conventional treatments like natural components more into consideration recently because of their reduced cost and adverse effects. Numerous studies have shown that the efficacy of natural products can influence various elements of cancer medication resistance. As described in this review, natural products have significant effects in overcoming drug resistance and enhancing the efficacy of chemotherapy. Natural products modulate inhibition of ABC transporters, increase in DNA damage, regulate ncRNA-mediated multidrug resistance, activate apoptotic cells, regulate the expression of metabolic enzymes, and chemosensitivity in various types of cancers both <italic>in vitro</italic> and <italic>in vivo</italic>.</p>
<p>Natural products are easily obtainable, but improving their qualities requires considering factors such as biological availability, biocompatibility, and half-life to enhance clinical efficacy and reduce risks to patients. To create more efficient antitumor drug delivery systems, the structure of tumor drugs is utilized to optimize drug properties. Additionally, computer-aided drug design can help in the development of natural products by predicting drug targets, modifying drug structure, and predicting toxicity. The focus of cancer therapeutic medication research is now on creating safe and effective natural products with fewer harmful side effects.</p>
<p>Patients who have developed medication resistance are being treated in clinical settings using a multi-targeted approach. For example, MET amplification causes cells to bypass EGFR and activate the PI3K/AKT pathway, allowing them to resist the effects of the EGFR inhibitors and develop resistance. For patients who have both MET amplification and EGFR mutations, the best treatment strategy is to use a dual-targeted EGFR/MET regimen to inhibit both EGFR and MET. To delay the development of resistance in KRAS-G12C patients, combination therapy is likely to become the preferred approach. When compared to mono-therapeutic regimens, combination techniques can significantly increase a therapy&#x2019;s safety and effectiveness, particularly if the combined medications have different modes of action. The creation of biomarker-driven therapeutics is the result of the identification of certain resistance mechanisms. Both targeting tactics that anticipate the selection of resistant and combinatorial strategies that target multiple resistance nodes are being considered. Clinical research on natural products currently available indicate that they are primarily adjuvant medications. For instance gemcitabine coupled with celecoxib and curcumin in the treatment of patients with pancreatic cancer, in a prospective phase II trial, the safety and efficacy of curcumin (2000&#xa0;mg/day in four capsules of 500&#xa0;mg each) and gemcitabine (10&#xa0;mg/m<sup>2</sup>) were evaluated in 44 patients with advanced and metastatic pancreatic cancer. The data showed a median progression-free survival and overall survival of 8.4 and 10.2 months, respectively. These findings suggest that the combination of gemcitabine and curcumin phytosome can safely and effectively increase the rate of response to first-line treatment for advanced pancreatic cancer. Natural substances may act as sensitizing agents in the therapy of cancer when used in combination, according to a growing body of research. In order to bring more effective treatments for reversing MDR to the clinic, it is crucial to uncover more potent and less dangerous chemicals and research their pharmacological mechanisms using cutting-edge technology, such as high-throughput screening methods, next-generation sequencing, advanced imaging techniques, and computational modeling. These technologies enable researchers to analyze complex biological systems at a molecular level, identify novel drug targets, and design innovative therapeutic strategies. By harnessing cutting-edge technology, scientists can accelerate the discovery and development of new drugs that can overcome multidrug resistance and improve patient outcomes. In order to encourage their clinical application and offer fresh ideas for the treatment of tumor drug resistance, this review covers the research progress of natural products in tumor drug resistance during the past few years.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Author contributions</title>
<p>J-YZ: Conceptualization, Data curation, Formal Analysis, Writing&#x2013;original draft. Q-LC: Writing&#x2013;original draft, and Writing&#x2013;review and editing. X-CL: Data curation, Writing&#x2013;original draft, and Writing&#x2013;review and editing. DD: Writing&#x2013;original draft, and Writing&#x2013;review and editing. UA: Writing&#x2013;original draft, and Writing&#x2013;review and editing. H-YL: Writing&#x2013;original draft, and Writing&#x2013;review and editing. TB: Writing&#x2013;original draft, and Writing&#x2013;review and editing. H-BC: Writing&#x2013;original draft, and Writing&#x2013;review and editing. Y-QW: Supervision, Formal Analysis, Writing&#x2013;original draft, and Writing&#x2013;review and editing. J-YZ: Funding acquisition, Resources, Supervision, Writing&#x2013;original draft, and Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s6">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Fund of Guangdong Science and Technology Department (2022A0505050080), the National Key R&#x0026;D Program of China (2021YFE0202000), the Fund of Guangzhou Science and Technology Program (202002030410), Innovation and Technology Fund in Hong Kong (MHP/023/20), the Affiliated Qingyuan Hospital of Guangzhou Medical University (202301-301), Ministry of Education Engineering Research Center of Tibetan Medicine Detection Technology (2022-ZYZXK07), Guangzhou Medical University Undergraduates project (pdjh 2022b0425, 02-410-2206301).</p>
</sec>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abadi</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Mirzaei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mahabady</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Hashemi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zabolian</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hashemi</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Curcumin and its derivatives in cancer therapy: potentiating antitumor activity of cisplatin and reducing side effects</article-title>. <source>Phytother. Res.</source> <volume>36</volume> (<issue>1</issue>), <fpage>189</fpage>&#x2013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.7305</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdelfatah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bockers</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Asensio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kadioglu</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Klinger</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fleischer</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells</article-title>. <source>Phytomedicine</source> <volume>86</volume>, <fpage>153196</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2020.153196</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Aschner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alsharif</surname>
<given-names>K. F.</given-names>
</name>
<name>
<surname>Albrakati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Saso</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy</article-title>. <source>Biomed. Pharmacother.</source> <volume>155</volume>, <fpage>113797</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.113797</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed-Belkacem</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pozza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mu&#xf1;oz-Mart&#xed;nez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Castanys</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gamarro</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2</article-title>. <source>Cancer Res.</source> <volume>65</volume> (<issue>11</issue>), <fpage>4852</fpage>&#x2013;<lpage>4860</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.Can-04-1817</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alkharashi</surname>
<given-names>N. A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Efficacy of resveratrol against breast cancer and hepatocellular carcinoma cell lines</article-title>. <source>Saudi Med. J.</source> <volume>44</volume> (<issue>3</issue>), <fpage>246</fpage>&#x2013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.15537/smj.2023.44.3.20220768</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ambudkar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kimchi-Sarfaty</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sauna</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gottesman</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>P-glycoprotein: from genomics to mechanism</article-title>. <source>Oncogene</source> <volume>22</volume> (<issue>47</issue>), <fpage>7468</fpage>&#x2013;<lpage>7485</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1206948</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amjad</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sokouti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Asnaashari</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound</article-title>. <source>Cancer Cell Int.</source> <volume>22</volume> (<issue>1</issue>), <fpage>260</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-022-02673-0</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arulselvan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fard</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Gothai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fakurazi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Norhaizan</surname>
<given-names>M. E.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Role of antioxidants and natural products in inflammation</article-title>. <source>Oxid. Med. Cell Longev.</source> <volume>2016</volume>, <fpage>5276130</fpage>. <pub-id pub-id-type="doi">10.1155/2016/5276130</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Assaraf</surname>
<given-names>Y. G.</given-names>
</name>
<name>
<surname>Brozovic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gon&#xe7;alves</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Jurkovicova</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lin&#x113;</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Machuqueiro</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The multi-factorial nature of clinical multidrug resistance in cancer</article-title>. <source>Drug Resist Updat</source> <volume>46</volume>, <fpage>100645</fpage>. <pub-id pub-id-type="doi">10.1016/j.drup.2019.100645</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Awad</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Katayama</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>McTigue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Brooun</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Acquired resistance to crizotinib from a mutation in CD74-ROS1</article-title>. <source>N. Engl. J. Med.</source> <volume>368</volume> (<issue>25</issue>), <fpage>2395</fpage>&#x2013;<lpage>2401</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1215530</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azizi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fouladdel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Komeili Movahhed</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Modaresi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Barzegar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ghahremani</surname>
<given-names>M. H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Quercetin effects on cell cycle arrest and apoptosis and doxorubicin activity in T47D cancer stem cells</article-title>. <source>Asian Pac J. Cancer Prev.</source> <volume>23</volume> (<issue>12</issue>), <fpage>4145</fpage>&#x2013;<lpage>4154</lpage>. <pub-id pub-id-type="doi">10.31557/apjcp.2022.23.12.4145</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barkley</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Moncada</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liberman</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Dryg</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Werba</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment</article-title>. <source>Nat. Genet.</source> <volume>54</volume> (<issue>8</issue>), <fpage>1192</fpage>&#x2013;<lpage>1201</lpage>. <pub-id pub-id-type="doi">10.1038/s41588-022-01141-9</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisht</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schlesinger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rupp</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nolting</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wenzel</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies</article-title>. <source>J. Nanobiotechnology</source> <volume>14</volume> (<issue>1</issue>), <fpage>57</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-016-0209-6</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bott</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Badders</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Harmison</surname>
<given-names>G. G.</given-names>
</name>
<name>
<surname>Bautista</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>C. C.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy</article-title>. <source>Hum. Mol. Genet.</source> <volume>25</volume> (<issue>10</issue>), <fpage>1979</fpage>&#x2013;<lpage>1989</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddw073</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buhrmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yazdi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Popper</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shayan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Goel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>B. B.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Resveratrol chemosensitizes TNF-&#x3b2;-induced survival of 5-FU-treated colorectal cancer cells</article-title>. <source>Nutrients</source> <volume>10</volume> (<issue>7</issue>), <fpage>888</fpage>. <pub-id pub-id-type="doi">10.3390/nu10070888</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakrawarti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gabrani</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Therapeutic effects of EGCG: a patent review</article-title>. <source>Expert Opin. Ther. Pat.</source> <volume>26</volume> (<issue>8</issue>), <fpage>907</fpage>&#x2013;<lpage>916</lpage>. <pub-id pub-id-type="doi">10.1080/13543776.2016.1203419</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>E. W. C.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>H. T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>An overview on the chemistry, pharmacology and anticancer properties of tetrandrine and fangchinoline (alkaloids) from Stephania tetrandra roots</article-title>. <source>J. Integr. Med.</source> <volume>19</volume> (<issue>4</issue>), <fpage>311</fpage>&#x2013;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1016/j.joim.2021.01.001</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>J. W.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: a key role of AMPK and Akt/mTOR signaling</article-title>. <source>Int. J. Oncol.</source> <volume>50</volume> (<issue>3</issue>), <fpage>873</fpage>&#x2013;<lpage>882</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2017.3866</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Targeting autophagy to overcome drug resistance: further developments</article-title>. <source>J. Hematol. Oncol.</source> <volume>13</volume> (<issue>1</issue>), <fpage>159</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-020-01000-2</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zeb</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>EGCG regulates CTR1 expression through its pro-oxidative property in non-small-cell lung cancer cells</article-title>. <source>J. Cell. physiology</source> <volume>235</volume> (<issue>11</issue>), <fpage>7970</fpage>&#x2013;<lpage>7981</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.29451</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1&#x3b1; signaling pathway</article-title>. <source>Oncol. Rep.</source> <volume>33</volume> (<issue>1</issue>), <fpage>457</fpage>&#x2013;<lpage>463</lpage>. <pub-id pub-id-type="doi">10.3892/or.2014.3550</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019a</year>). <article-title>A novel resveratrol-arsenic trioxide combination treatment synergistically induces apoptosis of adriamycin-selected drug-resistant leukemia K562 cells</article-title>. <source>J. Cancer</source> <volume>10</volume> (<issue>22</issue>), <fpage>5483</fpage>&#x2013;<lpage>5493</lpage>. <pub-id pub-id-type="doi">10.7150/jca.34506</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zha</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <fpage>35468</fpage>. <pub-id pub-id-type="doi">10.1038/srep35468</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Sze</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>May</surname>
<given-names>B. H.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Biological effects and mechanisms of matrine and other constituents of Sophora flavescens in colorectal cancer</article-title>. <source>Pharmacol. Res.</source> <volume>171</volume>, <fpage>105778</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2021.105778</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>P. Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C. H.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>AR ubiquitination induced by the curcumin analog suppresses growth of temozolomide-resistant glioblastoma through disrupting GPX4-Mediated redox homeostasis</article-title>. <source>Redox Biol.</source> <volume>30</volume>, <fpage>101413</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2019.101413</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Balan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Popovich</surname>
<given-names>D. G.</given-names>
</name>
</person-group> (<year>2019b</year>). <article-title>Review of ginseng anti-diabetic studies</article-title>. <source>Molecules</source> <volume>24</volume> (<issue>24</issue>), <fpage>4501</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24244501</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X. Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>C. F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>(-)-Epigallocatechin-3-Gallate inhibits colorectal cancer stem cells by suppressing wnt/&#x3b2;-catenin pathway</article-title>. <source>Nutrients</source> <volume>9</volume> (<issue>6</issue>), <fpage>572</fpage>. <pub-id pub-id-type="doi">10.3390/nu9060572</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1&#x3b1;</article-title>. <source>Clin. Transl. Med.</source> <volume>11</volume> (<issue>11</issue>), <fpage>e577</fpage>. <pub-id pub-id-type="doi">10.1002/ctm2.577</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Reversal effect of quercetin on multidrug resistance via FZD7/&#x3b2;-catenin pathway in hepatocellular carcinoma cells</article-title>. <source>Phytomedicine</source> <volume>43</volume>, <fpage>37</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2018.03.040</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S. I.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Molecular basis of resveratrol-induced resensitization of acquired drug-resistant cancer cells</article-title>. <source>Nutrients</source> <volume>14</volume> (<issue>3</issue>), <fpage>699</fpage>. <pub-id pub-id-type="doi">10.3390/nu14030699</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chong</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>I. L. K.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Characterization of a potent, selective, and safe inhibitor, Ac15(az8)(2), in reversing multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>21</issue>), <fpage>13261</fpage>. <pub-id pub-id-type="doi">10.3390/ijms232113261</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Condello</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pellegrini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Multari</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>F. R.</given-names>
</name>
<name>
<surname>Meschini</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Voacamine: alkaloid with its essential dimeric units to reverse tumor multidrug resistance</article-title>. <source>Toxicol Vitro</source> <volume>65</volume>, <fpage>104819</fpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2020.104819</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cort</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ozben</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Saso</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Korkina</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Redox control of multidrug resistance and its possible modulation by antioxidants</article-title>. <source>Oxid. Med. Cell Longev.</source> <volume>2016</volume>, <fpage>4251912</fpage>. <pub-id pub-id-type="doi">10.1155/2016/4251912</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Csik&#xf3;s</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Horv&#xe1;th</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>&#xc1;cs</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bal&#xe1;zs</surname>
<given-names>V. L.</given-names>
</name>
<name>
<surname>Dolenc</surname>
<given-names>M. S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Treatment of benign prostatic hyperplasia by natural drugs</article-title>. <source>Molecules</source> <volume>26</volume> (<issue>23</issue>), <fpage>7141</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26237141</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>da Costa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>G. I.</given-names>
</name>
<name>
<surname>D&#x27;Andrea</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Konstantinopoulos</surname>
<given-names>P. A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Targeting replication stress in cancer therapy</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>22</volume> (<issue>1</issue>), <fpage>38</fpage>&#x2013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-022-00558-5</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Debnath</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gammoh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Autophagy and autophagy-related pathways in cancer</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>24</volume> (<issue>8</issue>), <fpage>560</fpage>&#x2013;<lpage>575</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-023-00585-z</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>J. J.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review</article-title>. <source>Pharmacol. Ther.</source> <volume>249</volume>, <fpage>108488</fpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2023.108488</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer</article-title>. <source>Molecules</source> <volume>21</volume> (<issue>7</issue>), <fpage>965</fpage>. <pub-id pub-id-type="doi">10.3390/molecules21070965</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Efferth</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Saeed</surname>
<given-names>M. E. M.</given-names>
</name>
<name>
<surname>Kadioglu</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Shirooie</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mbaveng</surname>
<given-names>A. T.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Collateral sensitivity of natural products in drug-resistant cancer cells</article-title>. <source>Biotechnol. Adv.</source> <volume>38</volume>, <fpage>107342</fpage>. <pub-id pub-id-type="doi">10.1016/j.biotechadv.2019.01.009</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichhorn</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Efferth</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs</article-title>. <source>J. Ethnopharmacol.</source> <volume>141</volume> (<issue>2</issue>), <fpage>557</fpage>&#x2013;<lpage>570</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2011.08.053</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emran</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Shahriar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mahmud</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Abir</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Siddiquee</surname>
<given-names>M. F.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches</article-title>. <source>Front. Oncol.</source> <volume>12</volume>, <fpage>891652</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2022.891652</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erdogan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Doganlar</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Doganlar</surname>
<given-names>Z. B.</given-names>
</name>
<name>
<surname>Serttas</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Turkekul</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dibirdik</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>The flavonoid apigenin reduces prostate cancer CD44(&#x2b;) stem cell survival and migration through PI3K/Akt/NF-&#x3ba;B signaling</article-title>. <source>Life Sci.</source> <volume>162</volume>, <fpage>77</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2016.08.019</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erdogan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Turkekul</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Serttas</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Erdogan</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The natural flavonoid apigenin sensitizes human CD44(&#x2b;) prostate cancer stem cells to cisplatin therapy</article-title>. <source>Biomed. Pharmacother.</source> <volume>88</volume>, <fpage>210</fpage>&#x2013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.01.056</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>D. Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L. Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q. J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Natural products: potential treatments for cisplatin-induced nephrotoxicity</article-title>. <source>Acta Pharmacol. Sin.</source> <volume>42</volume> (<issue>12</issue>), <fpage>1951</fpage>&#x2013;<lpage>1969</lpage>. <pub-id pub-id-type="doi">10.1038/s41401-021-00620-9</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Felice</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Maugeri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Sarro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Navarra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Barreca</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Molecular pathways involved in the anti-cancer activity of flavonols: a focus on myricetin and kaempferol</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>8</issue>), <fpage>4411</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23084411</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fortuna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Falc&#xe3;o</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018a</year>). <article-title>Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: an <italic>in vitro</italic> evaluation with focus on antiepileptic drugs</article-title>. <source>Food Res. Int.</source> <volume>103</volume>, <fpage>110</fpage>&#x2013;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.foodres.2017.10.010</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Falc&#xe3;o</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018b</year>). <article-title>
<italic>In vitro</italic> screening of dual flavonoid combinations for reversing P-glycoprotein-mediated multidrug resistance: focus on antiepileptic drugs</article-title>. <source>Food Chem. Toxicol.</source> <volume>111</volume>, <fpage>84</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2017.11.004</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujiki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sueoka</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rawangkan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suganuma</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Cancer prevention with green tea and its principal constituent, EGCG: from early investigations to current focus on human cancer stem cells</article-title>. <source>Mol. Cells</source> <volume>41</volume> (<issue>2</issue>), <fpage>73</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.14348/molcells.2018.2227</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabr</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Elsaed</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Eladl</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>El-Sherbiny</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ebrahim</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Asseri</surname>
<given-names>S. M.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Curcumin modulates oxidative stress, fibrosis, and apoptosis in drug-resistant cancer cell lines</article-title>. <source>Life (Basel)</source> <volume>12</volume> (<issue>9</issue>), <fpage>1427</fpage>. <pub-id pub-id-type="doi">10.3390/life12091427</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghareghomi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Habibi-Rezaei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arese</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saso</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Moosavi-Movahedi</surname>
<given-names>A. A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Nrf2 modulation in breast cancer</article-title>. <source>Biomedicines</source> <volume>10</volume> (<issue>10</issue>), <fpage>2668</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines10102668</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giovannuzzi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nocentini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Capasso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Supuran</surname>
<given-names>C. T.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Coumarins inhibit eta-class carbonic anhydrase from Plasmodium falciparum</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source> <volume>37</volume> (<issue>1</issue>), <fpage>680</fpage>&#x2013;<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1080/14756366.2022.2036986</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs</article-title>. <source>Nutr. cancer</source> <volume>62</volume> (<issue>7</issue>), <fpage>919</fpage>&#x2013;<lpage>930</lpage>. <pub-id pub-id-type="doi">10.1080/01635581.2010.509835</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gon&#xe7;alves</surname>
<given-names>B. M. F.</given-names>
</name>
<name>
<surname>Cardoso</surname>
<given-names>D. S. P.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>M. J. U.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Overcoming multidrug resistance: flavonoid and terpenoid nitrogen-containing derivatives as ABC transporter modulators</article-title>. <source>Molecules</source> <volume>25</volume> (<issue>15</issue>), <fpage>3364</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25153364</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groelly</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Fawkes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dagg</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Blackford</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Tarsounas</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Targeting DNA damage response pathways in cancer</article-title>. <source>Nat. Rev. Cancer</source> <volume>23</volume> (<issue>2</issue>), <fpage>78</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-022-00535-5</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Bian</surname>
<given-names>Z. X.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>1401</volume> (<issue>1</issue>), <fpage>37</fpage>&#x2013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.13414</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Talukder</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bamimore</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Natural products for male androgenetic alopecia</article-title>. <source>Dermatol Ther.</source> <volume>35</volume> (<issue>4</issue>), <fpage>e15323</fpage>. <pub-id pub-id-type="doi">10.1111/dth.15323</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Wogonin induced G1 cell cycle arrest by regulating Wnt/&#x3b2;-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells</article-title>. <source>Toxicology</source> <volume>312</volume>, <fpage>36</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2013.07.013</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hegazy</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Dawood</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mahmoud</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Elbadawi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Klauck</surname>
<given-names>S. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>2&#x3b1;-Hydroxyalantolactone from Pulicaria undulata: activity against multidrug-resistant tumor cells and modes of action</article-title>. <source>Phytomedicine</source> <volume>81</volume>, <fpage>153409</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2020.153409</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heyza</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Conner</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Floyd</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Targeting the DNA repair endonuclease ERCC1-XPF with green tea polyphenol epigallocatechin-3-gallate (EGCG) and its prodrug to enhance cisplatin efficacy in human cancer cells</article-title>. <source>Nutrients</source> <volume>10</volume> (<issue>11</issue>), <fpage>1644</fpage>. <pub-id pub-id-type="doi">10.3390/nu10111644</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X. Q.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>J. X.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Bioactivities and mechanism of action of securinega alkaloids derivatives reported prior to 2022</article-title>. <source>Biomed. Pharmacother.</source> <volume>158</volume>, <fpage>114190</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.114190</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer</article-title>. <source>Oncotarget</source> <volume>6</volume> (<issue>17</issue>), <fpage>15348</fpage>&#x2013;<lpage>15361</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.3610</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review)</article-title>. <source>Oncol. Rep.</source> <volume>41</volume> (<issue>3</issue>), <fpage>1439</fpage>&#x2013;<lpage>1454</lpage>. <pub-id pub-id-type="doi">10.3892/or.2019.6962</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The antioxidant activities of natural polysaccharides</article-title>. <source>Curr. Drug Targets</source> <volume>18</volume> (<issue>11</issue>), <fpage>1296</fpage>&#x2013;<lpage>1300</lpage>. <pub-id pub-id-type="doi">10.2174/1389450118666170123145357</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A. Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rankin</surname>
<given-names>G. O.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Galangin, a flavonoid from lesser galangal, induced apoptosis via p53-dependent pathway in ovarian cancer cells</article-title>. <source>Molecules</source> <volume>25</volume> (<issue>7</issue>), <fpage>1579</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25071579</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hummelova</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rondevaldova</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Balastikova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lapcik</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Kokoska</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>The relationship between structure and <italic>in vitro</italic> antibacterial activity of selected isoflavones and their metabolites with special focus on antistaphylococcal effect of demethyltexasin</article-title>. <source>Lett. Appl. Microbiol.</source> <volume>60</volume> (<issue>3</issue>), <fpage>242</fpage>&#x2013;<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1111/lam.12361</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huynh</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gera</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017a</year>). <article-title>Wogonin suppresses stem cell-like traits of CD133 positive osteosarcoma cell via inhibiting matrix metallopeptidase-9 expression</article-title>. <source>BMC Complement. Altern. Med.</source> <volume>17</volume> (<issue>1</issue>), <fpage>304</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-017-1788-y</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huynh</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Ngau</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>N. H.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>G. B.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>C. T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Potential therapeutic and pharmacological effects of Wogonin: an updated review</article-title>. <source>Mol. Biol. Rep.</source> <volume>47</volume> (<issue>12</issue>), <fpage>9779</fpage>&#x2013;<lpage>9789</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-020-05972-9</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huynh</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kumar Singh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Singh Sodhi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Mongre</surname>
<given-names>R. K.</given-names>
</name>
<etal/>
</person-group> (<year>2017b</year>). <article-title>Anti-tumor activity of wogonin, an extract from Scutellaria baicalensis, through regulating different signaling pathways</article-title>. <source>Chin. J. Nat. Med.</source> <volume>15</volume> (<issue>1</issue>), <fpage>15</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/s1875-5364(17)30005-5</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ib&#xe1;&#xf1;ez Gaspar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>McMorrow</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The curcuminoid EF24 in combination with TRAIL reduces human renal cancer cell migration by decreasing MMP-2/MMP-9 activity through a reduction in H(2)O(2)</article-title>. <source>Int. J. Mol. Sci.</source> <volume>24</volume> (<issue>2</issue>), <fpage>1043</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24021043</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rauf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abu-Izneid</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nadeem</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shariati</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>I. A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Luteolin, a flavonoid, as an anticancer agent: a review</article-title>. <source>Biomed. Pharmacother.</source> <volume>112</volume>, <fpage>108612</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2019.108612</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Menaa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>N. U.</given-names>
</name>
<name>
<surname>Razzaq</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>Z. U.</given-names>
</name>
<name>
<surname>Ullah</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Two promising anti-cancer compounds, 2-hydroxycinnaldehyde and 2- benzoyloxycinnamaldehyde: where do we stand?</article-title> <source>Comb. Chem. High. Throughput Screen</source> <volume>25</volume> (<issue>5</issue>), <fpage>808</fpage>&#x2013;<lpage>818</lpage>. <pub-id pub-id-type="doi">10.2174/1386207324666210216094428</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobo-Albavera</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dom&#xed;nguez-P&#xe9;rez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Medina-Leyte</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez-Garrido</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Villarreal-Molina</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The role of the ATP-binding cassette A1 (ABCA1) in human disease</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>4</issue>), <fpage>1593</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22041593</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>A mini-review of flavone isomers apigenin and genistein in prostate cancer treatment</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>851589</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.851589</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Junren</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xiaofang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huiqiong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gangmin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yanpeng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xiaoyu</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Pharmacological activities and mechanisms of hirudin and its derivatives - a review</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>660757</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.660757</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasaian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mosaffa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Behravan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Masullo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Piacente</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ghandadi</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Reversal of P-glycoprotein-mediated multidrug resistance in MCF-7/Adr cancer cells by sesquiterpene coumarins</article-title>. <source>Fitoterapia</source> <volume>103</volume>, <fpage>149</fpage>&#x2013;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2015.03.025</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keyvani-Ghamsari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khorsandi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gul</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Curcumin effect on cancer cells&#x27; multidrug resistance: an update</article-title>. <source>Phytother. Res.</source> <volume>34</volume> (<issue>10</issue>), <fpage>2534</fpage>&#x2013;<lpage>2556</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6703</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Quispe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Javed</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Sadia</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Raza</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer</article-title>. <source>Cancer Cell Int.</source> <volume>20</volume> (<issue>1</issue>), <fpage>560</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-020-01660-7</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sohng</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>H. J.</given-names>
</name>
</person-group> (<year>2016a</year>). <article-title>Apigenin inhibits cancer stem cell-like phenotypes in human glioblastoma cells via suppression of c-met signaling</article-title>. <source>Phytother. Res.</source> <volume>30</volume> (<issue>11</issue>), <fpage>1833</fpage>&#x2013;<lpage>1840</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.5689</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Roh</surname>
<given-names>J. L.</given-names>
</name>
</person-group> (<year>2016b</year>). <article-title>Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer</article-title>. <source>Apoptosis</source> <volume>21</volume> (<issue>11</issue>), <fpage>1265</fpage>&#x2013;<lpage>1278</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-016-1284-8</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Wannatung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W. K.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>J. S.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Quercetin enhances hypoxia-mediated apoptosis via direct inhibition of AMPK activity in HCT116 colon cancer</article-title>. <source>Apoptosis</source> <volume>17</volume> (<issue>9</issue>), <fpage>938</fpage>&#x2013;<lpage>949</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-012-0719-0</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kokubo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ohnuma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Funayama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A phenylfurocoumarin derivative reverses ABCG2-mediated multidrug resistance <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>22</issue>), <fpage>12502</fpage>. <pub-id pub-id-type="doi">10.3390/ijms222212502</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Terpenoids from the medicinal mushroom Antrodia camphorata: chemistry and medicinal potential</article-title>. <source>Nat. Prod. Rep.</source> <volume>38</volume> (<issue>1</issue>), <fpage>83</fpage>&#x2013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1039/d0np00023j</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jaitak</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Natural products as multidrug resistance modulators in cancer</article-title>. <source>Eur. J. Med. Chem.</source> <volume>176</volume>, <fpage>268</fpage>&#x2013;<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2019.05.027</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Son</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Overcoming P-Glycoprotein-Mediated multidrug resistance in colorectal cancer: potential reversal agents among herbal medicines</article-title>. <source>Evid. Based Complement. Altern. Med.</source> <volume>2018</volume>, <fpage>3412074</fpage>. <pub-id pub-id-type="doi">10.1155/2018/3412074</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leinonen</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Kansanen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>P&#xf6;l&#xf6;nen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hein&#xe4;niemi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Levonen</surname>
<given-names>A. L.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Role of the Keap1-Nrf2 pathway in cancer</article-title>. <source>Adv. Cancer Res.</source> <volume>122</volume>, <fpage>281</fpage>&#x2013;<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-12-420117-0.00008-6</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Role of ncRNA in multiple myeloma</article-title>. <source>Biomark. Med.</source> <volume>16</volume> (<issue>16</issue>), <fpage>1181</fpage>&#x2013;<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.2217/bmm-2022-0349</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Krstin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wink</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018a</year>). <article-title>Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin</article-title>. <source>Phytomedicine</source> <volume>50</volume>, <fpage>213</fpage>&#x2013;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2018.09.169</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>MicroRNA-20a-5p inhibits the autophagy and cisplatin resistance in ovarian cancer via regulating DNMT3B-mediated DNA methylation of RBP1</article-title>. <source>Reprod. Toxicol.</source> <volume>109</volume>, <fpage>93</fpage>&#x2013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.reprotox.2021.12.011</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bie</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2018b</year>). <article-title>Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity</article-title>. <source>Biomed. Pharmacother.</source> <volume>98</volume>, <fpage>806</fpage>&#x2013;<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.01.002</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2018c</year>). <article-title>Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation</article-title>. <source>Phytother. Res.</source> <volume>32</volume> (<issue>8</issue>), <fpage>1530</fpage>&#x2013;<lpage>1536</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6081</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K. B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X. Q.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression</article-title>. <source>Autophagy</source> <volume>17</volume> (<issue>12</issue>), <fpage>4323</fpage>&#x2013;<lpage>4340</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2021.1912270</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020a</year>). <article-title>Tetrandrine partially reverses multidrug resistance of human laryngeal cancer cells</article-title>. <source>J. Int. Med. Res.</source> <volume>48</volume> (<issue>8</issue>), <fpage>300060520944706</fpage>. <pub-id pub-id-type="doi">10.1177/0300060520944706</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>W. C.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Autophagy and multidrug resistance in cancer</article-title>. <source>Chin. J. Cancer</source> <volume>36</volume> (<issue>1</issue>), <fpage>52</fpage>. <pub-id pub-id-type="doi">10.1186/s40880-017-0219-2</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020b</year>). <article-title>Matrine reverses the drug resistance of K562/ADM cells to ADM and VCR via promoting autophagy</article-title>. <source>Transl. Cancer Res.</source> <volume>9</volume> (<issue>2</issue>), <fpage>786</fpage>&#x2013;<lpage>794</lpage>. <pub-id pub-id-type="doi">10.21037/tcr.2019.12.11</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Lycorine induces apoptosis of acute myeloid leukemia cells and inhibits triglyceride production via binding and targeting FABP5</article-title>. <source>Ann. Hematol.</source> <volume>102</volume> (<issue>5</issue>), <fpage>1073</fpage>&#x2013;<lpage>1086</lpage>. <pub-id pub-id-type="doi">10.1007/s00277-023-05169-7</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy</article-title>. <source>Theranostics</source> <volume>10</volume> (<issue>8</issue>), <fpage>3366</fpage>&#x2013;<lpage>3381</lpage>. <pub-id pub-id-type="doi">10.7150/thno.41849</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Preliminary evaluation of the potential role of &#x3b2;-elemene in reversing erlotinib-resistant human NSCLC A549/ER cells</article-title>. <source>Oncol. Lett.</source> <volume>16</volume> (<issue>3</issue>), <fpage>3380</fpage>&#x2013;<lpage>3388</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2018.8980</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liskova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Samec</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koklesova</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kudela</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kubatka</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Golubnitschaja</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mitochondriopathies as a clue to systemic disorders-analytical tools and mitigating measures in context of predictive, preventive, and personalized (3P) medicine</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume> (<issue>4</issue>), <fpage>2007</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22042007</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019a</year>). <article-title>Alkaloids from traditional Chinese medicine against hepatocellular carcinoma</article-title>. <source>Biomed. Pharmacother.</source> <volume>120</volume>, <fpage>109543</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2019.109543</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review</article-title>. <source>Taiwan. J. obstetrics Gynecol.</source> <volume>48</volume> (<issue>3</issue>), <fpage>239</fpage>&#x2013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1016/s1028-4559(09)60296-5</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Curcumin sensitizes prostate cancer cells to radiation partly via epigenetic activation of miR-143 and miR-143 mediated autophagy inhibition</article-title>. <source>J. Drug Target</source> <volume>25</volume> (<issue>7</issue>), <fpage>645</fpage>&#x2013;<lpage>652</lpage>. <pub-id pub-id-type="doi">10.1080/1061186x.2017.1315686</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H. B.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Curcumin attenuates Adriamycin-resistance of acute myeloid leukemia by inhibiting the lncRNA HOTAIR/miR-20a-5p/WT1 axis</article-title>. <source>Lab. Invest.</source> <volume>101</volume> (<issue>10</issue>), <fpage>1308</fpage>&#x2013;<lpage>1317</lpage>. <pub-id pub-id-type="doi">10.1038/s41374-021-00640-3</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Puerarin sensitized K562/ADR cells by inhibiting NF-&#x3ba;B pathway and inducing autophagy</article-title>. <source>Phytother. Res.</source> <volume>35</volume> (<issue>3</issue>), <fpage>1658</fpage>&#x2013;<lpage>1668</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6932</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019b</year>). <article-title>FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1/AKT1/NF&#x3ba;B pathway</article-title>. <source>BMC Cancer</source> <volume>19</volume> (<issue>1</issue>), <fpage>679</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-019-5898-4</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Genistein mediates the selective radiosensitizing effect in NSCLC A549 cells via inhibiting methylation of the keap1 gene promoter region</article-title>. <source>Oncotarget</source> <volume>7</volume> (<issue>19</issue>), <fpage>27267</fpage>&#x2013;<lpage>27279</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.8403</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>C. T.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>7,3&#x27;,4&#x27;-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species</article-title>. <source>Toxicology</source> <volume>302</volume> (<issue>2-3</issue>), <fpage>221</fpage>&#x2013;<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2012.08.003</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lorendeau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dury</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Genoux-Bastide</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lecerf-Schmidt</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sim&#xf5;es-Pires</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carrupt</surname>
<given-names>P. A.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Collateral sensitivity of resistant MRP1-overexpressing cells to flavonoids and derivatives through GSH efflux</article-title>. <source>Biochem. Pharmacol.</source> <volume>90</volume> (<issue>3</issue>), <fpage>235</fpage>&#x2013;<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2014.05.017</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lorendeau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dury</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nasr</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Boumendjel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Teodori</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gutschow</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>MRP1-dependent collateral sensitivity of multidrug-resistant cancer cells: identifying selective modulators inducing cellular glutathione depletion</article-title>. <source>Curr. Med. Chem.</source> <volume>24</volume> (<issue>12</issue>), <fpage>1186</fpage>&#x2013;<lpage>1213</lpage>. <pub-id pub-id-type="doi">10.2174/0929867324666161118130238</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Low</surname>
<given-names>H. B.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>Z. L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>L. R.</given-names>
</name>
<name>
<surname>Png</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y. L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death</article-title>. <source>Nat. Commun.</source> <volume>12</volume> (<issue>1</issue>), <fpage>2284</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-22638-7</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jian</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial</article-title>. <source>Lancet Oncol.</source> <volume>23</volume> (<issue>9</issue>), <fpage>1167</fpage>&#x2013;<lpage>1179</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(22)00382-5</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luca</surname>
<given-names>S. V.</given-names>
</name>
<name>
<surname>Macovei</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bujor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miron</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Skalicka-Wozniak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aprotosoaie</surname>
<given-names>A. C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Bioactivity of dietary polyphenols: the role of metabolites</article-title>. <source>Crit. Rev. Food Sci. Nutr.</source> <volume>60</volume> (<issue>4</issue>), <fpage>626</fpage>&#x2013;<lpage>659</lpage>. <pub-id pub-id-type="doi">10.1080/10408398.2018.1546669</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Antioxidant and anti-diabetic activities of polysaccharides from guava leaves</article-title>. <source>Molecules</source> <volume>24</volume> (<issue>7</issue>), <fpage>1343</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24071343</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maleki Dana</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sadoughi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mirzaei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Asemi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yousefi</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>DNA damage response and repair in the development and treatment of brain tumors</article-title>. <source>Eur. J. Pharmacol.</source> <volume>924</volume>, <fpage>174957</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2022.174957</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mans</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>da Rocha</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Schwartsmann</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds</article-title>. <source>Oncologist</source> <volume>5</volume> (<issue>3</issue>), <fpage>185</fpage>&#x2013;<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1634/theoncologist.5-3-185</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Perrone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yousefi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Papini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Castiglione</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guarino</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Botanical, phytochemical, anti-microbial and pharmaceutical characteristics of hawthorn (crataegusmonogyna jacq.), rosaceae</article-title>. <source>Molecules</source> <volume>26</volume> (<issue>23</issue>), <fpage>7266</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26237266</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meiyanto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Putri</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Susidarti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Murwanti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fitriasari</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation</article-title>. <source>Asian Pac. J. cancer Prev.</source> <volume>15</volume> (<issue>1</issue>), <fpage>179</fpage>&#x2013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.7314/apjcp.2014.15.1.179</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition</article-title>. <source>Int. J. Pharm.</source> <volume>513</volume> (<issue>1-2</issue>), <fpage>8</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.09.001</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohammad</surname>
<given-names>I. S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR</article-title>. <source>Biomed. Pharmacother.</source> <volume>100</volume>, <fpage>335</fpage>&#x2013;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.02.038</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montagut</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dalmases</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bellosillo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Crespo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pairet</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iglesias</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer</article-title>. <source>Nat. Med.</source> <volume>18</volume> (<issue>2</issue>), <fpage>221</fpage>&#x2013;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2609</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mortezaee</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Najafi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Farhood</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ahmadi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shabeeb</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Musa</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019a</year>). <article-title>NF-&#x3ba;B targeting for overcoming tumor resistance and normal tissues toxicity</article-title>. <source>J. Cell. physiology</source> <volume>234</volume> (<issue>10</issue>), <fpage>17187</fpage>&#x2013;<lpage>17204</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.28504</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mortezaee</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Salehi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mirtavoos-Mahyari</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Motevaseli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Najafi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Farhood</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2019b</year>). <article-title>Mechanisms of apoptosis modulation by curcumin: implications for cancer therapy</article-title>. <source>J. Cell Physiol.</source> <volume>234</volume> (<issue>8</issue>), <fpage>12537</fpage>&#x2013;<lpage>12550</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.28122</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murakami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohnuma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chufan</surname>
<given-names>E. E.</given-names>
</name>
<name>
<surname>Kudoh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kanehara</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Synthetic analogs of curcumin modulate the function of multidrug resistance-linked ATP-binding cassette transporter ABCG2</article-title>. <source>Drug Metab. Dispos.</source> <volume>45</volume> (<issue>11</issue>), <fpage>1166</fpage>&#x2013;<lpage>1177</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.117.076000</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noorian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chamani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Salmani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rezaei</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Khorsandi</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Effects of doxorubicin and apigenin on chronic myeloid leukemia cells (K562) <italic>in vitro</italic>: anti-proliferative and apoptosis induction assessments</article-title>. <source>Nat. Prod. Res.</source> <volume>37</volume>, <fpage>3335</fpage>&#x2013;<lpage>3343</lpage>. <pub-id pub-id-type="doi">10.1080/14786419.2022.2069765</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panieri</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pinho</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Afonso</surname>
<given-names>G. J. M.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Cunha-Oliveira</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Saso</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>NRF2 and mitochondrial function in cancer and cancer stem cells</article-title>. <source>Cells</source> <volume>11</volume> (<issue>15</issue>), <fpage>2401</fpage>. <pub-id pub-id-type="doi">10.3390/cells11152401</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papadochristopoulos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kerry</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Fegan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Duffy</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Natural anti-microbials for enhanced microbial safety and shelf-life of processed packaged meat</article-title>. <source>Foods</source> <volume>10</volume> (<issue>7</issue>), <fpage>1598</fpage>. <pub-id pub-id-type="doi">10.3390/foods10071598</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Nam-Goong</surname>
<given-names>I. S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. I.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E. S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Combined effects of baicalein and Docetaxel on apoptosis in 8505c anaplastic thyroid cancer cells via downregulation of the ERK and akt/mTOR pathways</article-title>. <source>Endocrinol. Metab. Seoul.</source> <volume>33</volume> (<issue>1</issue>), <fpage>121</fpage>&#x2013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.3803/EnM.2018.33.1.121</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penson</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Banach</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Natural compounds as anti-atherogenic agents: clinical evidence for improved cardiovascular outcomes</article-title>. <source>Atherosclerosis</source> <volume>316</volume>, <fpage>58</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2020.11.015</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Punia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Raina</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>R. P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells</article-title>. <source>PLoS One</source> <volume>12</volume> (<issue>8</issue>), <fpage>e0182870</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0182870</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rakesh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>PriyaDharshini</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Sakthivel</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Rasmi</surname>
<given-names>R. R.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Role and regulation of autophagy in cancer</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source> <volume>1868</volume> (<issue>7</issue>), <fpage>166400</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2022.166400</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kwah</surname>
<given-names>M. X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shanmugam</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Resveratrol for cancer therapy: challenges and future perspectives</article-title>. <source>Cancer Lett.</source> <volume>515</volume>, <fpage>63</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2021.05.001</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riahi-Chebbi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Souid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Othman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Haoues</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karoui</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Morel</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells</article-title>. <source>Sci. Rep.</source> <volume>9</volume> (<issue>1</issue>), <fpage>195</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-36808-z</pub-id>
</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robey</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Polgar</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Deeken</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>To</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>ABCG2: determining its relevance in clinical drug resistance</article-title>. <source>Cancer metastasis Rev.</source> <volume>26</volume> (<issue>1</issue>), <fpage>39</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-007-9042-6</pub-id>
</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rong</surname>
<given-names>L. W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R. X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X. Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition</article-title>. <source>Oncol. Lett.</source> <volume>13</volume> (<issue>6</issue>), <fpage>5028</fpage>&#x2013;<lpage>5034</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2017.6059</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Lycorine: a prospective natural lead for anticancer drug discovery</article-title>. <source>Biomed. Pharmacother.</source> <volume>107</volume>, <fpage>615</fpage>&#x2013;<lpage>624</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.07.147</pub-id>
</citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Lycorine downregulates HMGB1 to inhibit autophagy and enhances bortezomib activity in multiple myeloma</article-title>. <source>Theranostics</source> <volume>6</volume> (<issue>12</issue>), <fpage>2209</fpage>&#x2013;<lpage>2224</lpage>. <pub-id pub-id-type="doi">10.7150/thno.15584</pub-id>
</citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rudnicka</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Napierala</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Podfigurna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Meczekalski</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Smolarczyk</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Grymowicz</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The World Health Organization (WHO) approach to healthy ageing</article-title>. <source>Maturitas</source> <volume>139</volume>, <fpage>6</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.maturitas.2020.05.018</pub-id>
</citation>
</ref>
<ref id="B139">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sajadimajd</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khazaei</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Oxidative stress and cancer: the role of Nrf2</article-title>. <source>Curr. Cancer Drug Targets</source> <volume>18</volume> (<issue>6</issue>), <fpage>538</fpage>&#x2013;<lpage>557</lpage>. <pub-id pub-id-type="doi">10.2174/1568009617666171002144228</pub-id>
</citation>
</ref>
<ref id="B140">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sancha</surname>
<given-names>S. A. R.</given-names>
</name>
<name>
<surname>Szemer&#xe9;di</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Spengler</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>M. U.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Lycorine carbamate derivatives for reversing P-glycoprotein-Mediated multidrug resistance in human colon adenocarcinoma cells</article-title>. <source>Int. J. Mol. Sci.</source> <volume>24</volume> (<issue>3</issue>), <fpage>2061</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24032061</pub-id>
</citation>
</ref>
<ref id="B141">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saraei</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Soleimani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Asghari-Jafarabadi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Naimi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hassanzadeh</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Kaempferol sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistance chronic myelogenous leukemia cells to apoptosis</article-title>. <source>Mol. Biol. Rep.</source> <volume>49</volume> (<issue>1</issue>), <fpage>19</fpage>&#x2013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-021-06778-z</pub-id>
</citation>
</ref>
<ref id="B142">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkadi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Homolya</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Szak&#xe1;cs</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>V&#xe1;radi</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system</article-title>. <source>Physiol. Rev.</source> <volume>86</volume> (<issue>4</issue>), <fpage>1179</fpage>&#x2013;<lpage>1236</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00037.2005</pub-id>
</citation>
</ref>
<ref id="B143">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>K. D.</given-names>
</name>
<name>
<surname>Wagle</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Cancer statistics, 2023</article-title>. <source>CA Cancer J. Clin.</source> <volume>73</volume> (<issue>1</issue>), <fpage>17</fpage>&#x2013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21763</pub-id>
</citation>
</ref>
<ref id="B144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Assaraf</surname>
<given-names>Y. G.</given-names>
</name>
<name>
<surname>Gacche</surname>
<given-names>R. N.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Long non-coding RNA mediated drug resistance in breast cancer</article-title>. <source>Drug Resist Updat</source> <volume>63</volume>, <fpage>100851</fpage>. <pub-id pub-id-type="doi">10.1016/j.drup.2022.100851</pub-id>
</citation>
</ref>
<ref id="B145">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Meena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Luqman</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Acacetin, a flavone with diverse therapeutic potential in cancer, inflammation, infections and other metabolic disorders</article-title>. <source>Food Chem. Toxicol.</source> <volume>145</volume>, <fpage>111708</fpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2020.111708</pub-id>
</citation>
</ref>
<ref id="B146">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skok</surname>
<given-names>&#x17d;.</given-names>
</name>
<name>
<surname>Zidar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kikelj</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ila&#x161;</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Dual inhibitors of human DNA topoisomerase II and other cancer-related targets</article-title>. <source>J. Med. Chem.</source> <volume>63</volume> (<issue>3</issue>), <fpage>884</fpage>&#x2013;<lpage>904</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00726</pub-id>
</citation>
</ref>
<ref id="B147">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>Y. Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Improved drug delivery and anti-tumor efficacy of combinatorial liposomal formulation of genistein and plumbagin by targeting Glut1 and Akt3 proteins in mice bearing prostate tumor</article-title>. <source>Colloids Surf. B Biointerfaces</source> <volume>190</volume>, <fpage>110966</fpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.110966</pub-id>
</citation>
</ref>
<ref id="B148">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Hsin</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>F. L.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>EF-24, a curcumin analog, inhibits cancer cell invasion in human nasopharyngeal carcinoma through transcriptional suppression of matrix metalloproteinase-9 gene expression</article-title>. <source>Cancers (Basel)</source> <volume>15</volume> (<issue>5</issue>), <fpage>1552</fpage>. <pub-id pub-id-type="doi">10.3390/cancers15051552</pub-id>
</citation>
</ref>
<ref id="B150">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sung</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Laversanne</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soerjomataram</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J. Clin.</source> <volume>71</volume> (<issue>3</issue>), <fpage>209</fpage>&#x2013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
</citation>
</ref>
<ref id="B151">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamaddonfard</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Erfanparast</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Farshid</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Imani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mirzakhani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Salighedar</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Safranal, a constituent of saffron, exerts gastro-protective effects against indomethacin-induced gastric ulcer</article-title>. <source>Life Sci.</source> <volume>224</volume>, <fpage>88</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2019.03.054</pub-id>
</citation>
</ref>
<ref id="B152">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Recent advances in understanding the mechanisms of elemene in reversing drug resistance in tumor cells: a review</article-title>. <source>Molecules</source> <volume>26</volume> (<issue>19</issue>), <fpage>5792</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26195792</pub-id>
</citation>
</ref>
<ref id="B153">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer</article-title>. <source>Oncotarget</source> <volume>8</volume> (<issue>47</issue>), <fpage>82842</fpage>&#x2013;<lpage>82853</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.20666</pub-id>
</citation>
</ref>
<ref id="B154">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tavares-Valente</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Baltazar</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Queir&#xf3;s</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin</article-title>. <source>J. Bioenerg. Biomembr.</source> <volume>45</volume> (<issue>5</issue>), <fpage>467</fpage>&#x2013;<lpage>475</lpage>. <pub-id pub-id-type="doi">10.1007/s10863-013-9519-7</pub-id>
</citation>
</ref>
<ref id="B155">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Theissinger</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Formenti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bista</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Bleidorn</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>How genomics can help biodiversity conservation</article-title>. <source>Trends Genet.</source> <volume>39</volume> (<issue>7</issue>), <fpage>545</fpage>&#x2013;<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1016/j.tig.2023.01.005</pub-id>
</citation>
</ref>
<ref id="B156">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiwari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Trivedi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S. Y.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Tumor microenvironment: barrier or opportunity towards effective cancer therapy</article-title>. <source>J. Biomed. Sci.</source> <volume>29</volume> (<issue>1</issue>), <fpage>83</fpage>. <pub-id pub-id-type="doi">10.1186/s12929-022-00866-3</pub-id>
</citation>
</ref>
<ref id="B157">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomeh</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Hadianamrei</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>A review of curcumin and its derivatives as anticancer agents</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume> (<issue>5</issue>), <fpage>1033</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20051033</pub-id>
</citation>
</ref>
<ref id="B158">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Curcumin-induced DNA demethylation in human gastric cancer cells is mediated by the DNA-damage response pathway</article-title>. <source>Oxid. Med. Cell Longev.</source> <volume>2020</volume>, <fpage>2543504</fpage>. <pub-id pub-id-type="doi">10.1155/2020/2543504</pub-id>
</citation>
</ref>
<ref id="B159">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villegas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sterner</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez-Chavarr&#xed;a</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Paz</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Curcuma as an adjuvant in colorectal cancer treatment</article-title>. <source>Life Sci.</source> <volume>286</volume>, <fpage>120043</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2021.120043</pub-id>
</citation>
</ref>
<ref id="B160">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vissenaekens</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Criel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Grootaert</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Raes</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Smagghe</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Van Camp</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Flavonoids and cellular stress: a complex interplay affecting human health</article-title>. <source>Crit. Rev. Food Sci. Nutr.</source> <volume>62</volume> (<issue>31</issue>), <fpage>8535</fpage>&#x2013;<lpage>8566</lpage>. <pub-id pub-id-type="doi">10.1080/10408398.2021.1929822</pub-id>
</citation>
</ref>
<ref id="B161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vlahopoulos</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Aberrant control of NF-&#x3ba;B in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode</article-title>. <source>Cancer Biol. Med.</source> <volume>14</volume> (<issue>3</issue>), <fpage>254</fpage>&#x2013;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2017.0029</pub-id>
</citation>
</ref>
<ref id="B162">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z. F.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B. A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Application of alkaloids in reversing multidrug resistance in human cancers</article-title>. <source>Chin. J. Nat. Med.</source> <volume>16</volume> (<issue>8</issue>), <fpage>561</fpage>&#x2013;<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1016/S1875-5364(18)30093-1</pub-id>
</citation>
</ref>
<ref id="B163">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Tumor immunomodulatory effects of polyphenols</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>1041138</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.1041138</pub-id>
</citation>
</ref>
<ref id="B164">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer</article-title>. <source>PLoS One</source> <volume>10</volume> (<issue>4</issue>), <fpage>e0125402</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0125402</pub-id>
</citation>
</ref>
<ref id="B165">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shriwas</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Extracellular ATP, as an energy and phosphorylating molecule, induces different types of drug resistances in cancer cells through ATP internalization and intracellular ATP level increase</article-title>. <source>Oncotarget</source> <volume>8</volume> (<issue>50</issue>), <fpage>87860</fpage>&#x2013;<lpage>87877</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.21231</pub-id>
</citation>
</ref>
<ref id="B166">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Resveratrol sensitizes colorectal cancer cells to cetuximab by connexin 43 upregulation-induced Akt inhibition</article-title>. <source>Front. Oncol.</source> <volume>10</volume>, <fpage>383</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2020.00383</pub-id>
</citation>
</ref>
<ref id="B167">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-&#x3ba;B-Nrf2 signaling in colorectal cancer cell</article-title>. <source>Phytomedicine</source> <volume>82</volume>, <fpage>153414</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2020.153414</pub-id>
</citation>
</ref>
<ref id="B168">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>K. K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>DNMT1: a key drug target in triple-negative breast cancer</article-title>. <source>Semin. Cancer Biol.</source> <volume>72</volume>, <fpage>198</fpage>&#x2013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2020.05.010</pub-id>
</citation>
</ref>
<ref id="B169">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Kaempferol can reverse the 5-fu resistance of colorectal cancer cells by inhibiting PKM2-mediated glycolysis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>7</issue>), <fpage>3544</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23073544</pub-id>
</citation>
</ref>
<ref id="B170">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Curcumin increases exosomal TCF21 thus suppressing exosome-induced lung cancer</article-title>. <source>Oncotarget</source> <volume>7</volume> (<issue>52</issue>), <fpage>87081</fpage>&#x2013;<lpage>87090</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.13499</pub-id>
</citation>
</ref>
<ref id="B171">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Oyang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Role of the NF&#x3ba;B-signaling pathway in cancer</article-title>. <source>OncoTargets Ther.</source> <volume>11</volume>, <fpage>2063</fpage>&#x2013;<lpage>2073</lpage>. <pub-id pub-id-type="doi">10.2147/ott.S161109</pub-id>
</citation>
</ref>
<ref id="B172">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>(-)-Epigallocatechin-3-gallate induces cell apoptosis in chronic myeloid leukaemia by regulating Bcr/Abl-mediated p38-MAPK/JNK and JAK2/STAT3/AKT signalling pathways</article-title>. <source>Clin. Exp. Pharmacol. Physiol.</source> <volume>46</volume> (<issue>2</issue>), <fpage>126</fpage>&#x2013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1111/1440-1681.13037</pub-id>
</citation>
</ref>
<ref id="B173">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiaokaiti</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Natural product regulates autophagy in cancer</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>1207</volume>, <fpage>709</fpage>&#x2013;<lpage>724</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-15-4272-5_53</pub-id>
</citation>
</ref>
<ref id="B174">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Sui</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Autophagy inhibition mediated by MCOLN1/TRPML1 suppresses cancer metastasis via regulating a ROS-driven TP53/p53 pathway</article-title>. <source>Autophagy</source> <volume>18</volume> (<issue>8</issue>), <fpage>1932</fpage>&#x2013;<lpage>1954</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2021.2008752</pub-id>
</citation>
</ref>
<ref id="B175">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway</article-title>. <source>Biochem. Pharmacol.</source> <volume>92</volume> (<issue>2</issue>), <fpage>220</fpage>&#x2013;<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2014.09.008</pub-id>
</citation>
</ref>
<ref id="B176">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>H. F.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Dihydromyricetin induces apoptosis and reverses drug resistance in ovarian cancer cells by p53-mediated downregulation of survivin</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>46060</fpage>. <pub-id pub-id-type="doi">10.1038/srep46060</pub-id>
</citation>
</ref>
<ref id="B177">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aljitawi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Van Veldhuizen</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Prostate cancer stem cells: the role of CD133</article-title>. <source>Cancers (Basel)</source> <volume>14</volume> (<issue>21</issue>), <fpage>5448</fpage>. <pub-id pub-id-type="doi">10.3390/cancers14215448</pub-id>
</citation>
</ref>
<ref id="B178">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>MicroRNA-92a-3p enhances cisplatin resistance by regulating kr&#xfc;ppel-like factor 4-mediated cell apoptosis and epithelial-to-mesenchymal transition in cervical cancer</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>783213</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.783213</pub-id>
</citation>
</ref>
<ref id="B179">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand <italic>in vivo</italic> through ROS-mediated downregulation of cFLIPL and IAP proteins</article-title>. <source>Apoptosis</source> <volume>18</volume> (<issue>5</issue>), <fpage>618</fpage>&#x2013;<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-013-0808-8</pub-id>
</citation>
</ref>
<ref id="B180">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Reversal of multidrug resistance in cancer by multi-functional flavonoids</article-title>. <source>Front. Oncol.</source> <volume>9</volume>, <fpage>487</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2019.00487</pub-id>
</citation>
</ref>
<ref id="B181">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C. G.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Interactions between natural products and tamoxifen in breast cancer: a comprehensive literature review</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>847113</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.847113</pub-id>
</citation>
</ref>
<ref id="B182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017a</year>). <article-title>Lycorine promotes autophagy and apoptosis via TCRP1/akt/mTOR Axis inactivation in human hepatocellular carcinoma</article-title>. <source>Mol. Cancer Ther.</source> <volume>16</volume> (<issue>12</issue>), <fpage>2711</fpage>&#x2013;<lpage>2723</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.Mct-17-0498</pub-id>
</citation>
</ref>
<ref id="B183">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xiaoxiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2017b</year>). <article-title>Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-&#x3ba;B pathway</article-title>. <source>Biomed. Pharmacother.</source> <volume>90</volume>, <fpage>677</fpage>&#x2013;<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.04.001</pub-id>
</citation>
</ref>
<ref id="B184">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N. F.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y. F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-&#x3ba;B and Bcl-2/Bax signaling pathways</article-title>. <source>Biomed. Pharmacother.</source> <volume>97</volume>, <fpage>213</fpage>&#x2013;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.10.059</pub-id>
</citation>
</ref>
<ref id="B185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X. M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Simplified derivatives of tetrandrine as potent and specific P-gp inhibitors to reverse multidrug resistance in cancer chemotherapy</article-title>. <source>J. Med. Chem.</source> <volume>66</volume> (<issue>6</issue>), <fpage>4086</fpage>&#x2013;<lpage>4105</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c02061</pub-id>
</citation>
</ref>
<ref id="B186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H. D.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y. F.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J. H.</given-names>
</name>
</person-group> (<year>2015a</year>). <article-title>&#x3b2;-Elemene reverses chemoresistance of breast cancer cells by reducing resistance transmission via exosomes</article-title>. <source>Cell Physiol. Biochem.</source> <volume>36</volume> (<issue>6</issue>), <fpage>2274</fpage>&#x2013;<lpage>2286</lpage>. <pub-id pub-id-type="doi">10.1159/000430191</pub-id>
</citation>
</ref>
<ref id="B187">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z. S.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells</article-title>. <source>Mol. Cancer</source> <volume>21</volume> (<issue>1</issue>), <fpage>103</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-022-01524-w</pub-id>
</citation>
</ref>
<ref id="B188">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The strategies and techniques of drug discovery from natural products</article-title>. <source>Pharmacol. Ther.</source> <volume>216</volume>, <fpage>107686</fpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107686</pub-id>
</citation>
</ref>
<ref id="B189">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z. S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers</article-title>. <source>Acta Pharm. Sin. B</source> <volume>13</volume> (<issue>3</issue>), <fpage>982</fpage>&#x2013;<lpage>997</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2022.10.002</pub-id>
</citation>
</ref>
<ref id="B190">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2022b</year>). <article-title>Remodeling tumor microenvironment with natural products to overcome drug resistance</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>1051998</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.1051998</pub-id>
</citation>
</ref>
<ref id="B191">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2015b</year>). <article-title>Quercetin enhances cisplatin sensitivity of human osteosarcoma cells by modulating microRNA-217-KRAS Axis</article-title>. <source>Mol. Cells</source> <volume>38</volume> (<issue>7</issue>), <fpage>638</fpage>&#x2013;<lpage>642</lpage>. <pub-id pub-id-type="doi">10.14348/molcells.2015.0037</pub-id>
</citation>
</ref>
<ref id="B192">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2022c</year>). <article-title>Natural polyphenols for treatment of colorectal cancer</article-title>. <source>Molecules</source> <volume>27</volume> (<issue>24</issue>), <fpage>8810</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27248810</pub-id>
</citation>
</ref>
<ref id="B193">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Curcumin sensitizes lymphoma cells to DNA damage agents through regulating Rad51-dependent homologous recombination</article-title>. <source>Biomed. Pharmacother.</source> <volume>97</volume>, <fpage>115</fpage>&#x2013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.09.078</pub-id>
</citation>
</ref>
<ref id="B194">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Natural polysaccharides with immunomodulatory activities</article-title>. <source>Mini Rev. Med. Chem.</source> <volume>20</volume> (<issue>2</issue>), <fpage>96</fpage>&#x2013;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.2174/1389557519666190913151632</pub-id>
</citation>
</ref>
<ref id="B195">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression</article-title>. <source>Gene</source> <volume>622</volume>, <fpage>1</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2017.04.026</pub-id>
</citation>
</ref>
<ref id="B196">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kuang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2022a</year>). <article-title>Non-coding RNA in cancer drug resistance: underlying mechanisms and clinical applications</article-title>. <source>Front. Oncol.</source> <volume>12</volume>, <fpage>951864</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2022.951864</pub-id>
</citation>
</ref>
<ref id="B197">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022b</year>). <article-title>Tetrandrine overcomes drug resistance mediated by bone marrow microenvironment by regulating the expression of P-glycoprotein in acute leukemia</article-title>. <source>Hematology</source> <volume>27</volume> (<issue>1</issue>), <fpage>274</fpage>&#x2013;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1080/16078454.2022.2034256</pub-id>
</citation>
</ref>
<ref id="B198">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Rutaecarpine increases anticancer drug sensitivity in drug-resistant cells through MARCH8-dependent ABCB1 degradation</article-title>. <source>Biomedicines</source> <volume>9</volume> (<issue>9</issue>), <fpage>1143</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines9091143</pub-id>
</citation>
</ref>
<ref id="B199">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zong</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression</article-title>. <source>J. Cell Mol. Med.</source> <volume>21</volume> (<issue>9</issue>), <fpage>1929</fpage>&#x2013;<lpage>1943</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13114</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>